AU2001264563A1 - Albumin fusion proteins - Google Patents

Albumin fusion proteins

Info

Publication number: AU2001264563A1
Authority: AU; Australia
Prior art keywords: fusion proteins; albumin fusion; albumin; proteins; fusion
Prior art date: 2000-04-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001264563A

Inventor

William A. Haseltine

Craig A Rosen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Human Genome Sciences Inc

Original Assignee

Human Genome Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-12

Filing date

2001-04-12

Publication date

2001-10-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001264563(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-04-12 Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc

2001-10-30 Publication of AU2001264563A1 publication Critical patent/AU2001264563A1/en

Status Abandoned legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Virology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)

AU2001264563A 2000-04-12 2001-04-12 Albumin fusion proteins Abandoned AU2001264563A1 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US22935800P	2000-04-12	2000-04-12
US60229358		2000-04-12
US19938400P	2000-04-25	2000-04-25
US60199384		2000-04-25
US25693100P	2000-12-21	2000-12-21
US60256931		2000-12-21
PCT/US2001/011850 WO2001079442A2 (en)	2000-04-12	2001-04-12	Albumin fusion proteins

Publications (1)

Publication Number	Publication Date
AU2001264563A1 true AU2001264563A1 (en)	2001-10-30

Family

ID=27394014

Family Applications (7)

Application Number	Title	Priority Date	Filing Date
AU2001262942A Abandoned AU2001262942A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001259063A Abandoned AU2001259063A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001274809A Abandoned AU2001274809A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001261024A Abandoned AU2001261024A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001264563A Abandoned AU2001264563A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001266557A Abandoned AU2001266557A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001259066A Abandoned AU2001259066A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins

Family Applications Before (4)

Application Number	Title	Priority Date	Filing Date
AU2001262942A Abandoned AU2001262942A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001259063A Abandoned AU2001259063A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001274809A Abandoned AU2001274809A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001261024A Abandoned AU2001261024A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
AU2001266557A Abandoned AU2001266557A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001259066A Abandoned AU2001259066A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins

Country Status (10)

Country	Link
US (23)	US6926898B2 (en)
EP (21)	EP2357008A1 (en)
JP (9)	JP2003530839A (en)
AU (7)	AU2001262942A1 (en)
BE (1)	BE2016C059I2 (en)
CA (8)	CA2405709A1 (en)
DK (2)	DK2216409T3 (en)
ES (2)	ES2484966T3 (en)
FR (1)	FR16C0043I2 (en)
WO (7)	WO2001079271A1 (en)

Families Citing this family (668)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (en) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
GB9526733D0 (en)	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
WO2002068638A1 (en) *	2001-02-23	2002-09-06	Human Genome Sciences, Inc.	83 human secreted proteins
WO2002016389A1 (en) *	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	23 human secreted proteins
US20020137890A1 (en)	1997-03-31	2002-09-26	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP0892047A3 (en) *	1997-07-09	2000-03-08	Hoechst Marion Roussel Deutschland GmbH	Human and murine semaphorin L
US20030166108A1 (en) *	1997-09-18	2003-09-04	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE339507T1 (en) *	1998-06-15	2006-10-15	Gtc Biotherapeutics Inc	ERYTHROPOIETIN ANALOG HUMAN SERUM-ALBUMIN FUSION PROTEIN
US20050181482A1 (en) *	2004-02-12	2005-08-18	Meade Harry M.	Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
US20040199099A1 (en) *	1998-07-10	2004-10-07	Matson James R	Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
KR20020002354A (en)	1998-10-13	2002-01-09	추후제출	Stabilized bioactive peptides and methods of identification, synthesis and use
US20030190740A1 (en)	1998-10-13	2003-10-09	The University Of Georgia Research Foundation, Inc	Stabilized bioactive peptides and methods of identification, synthesis, and use
ES2402878T3 (en) *	1999-05-05	2013-05-10	Phylogica Limited	Isolation of biological modulators from collections of biogenic gene fragments
US6946129B1 (en) *	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
US7632803B2 (en)	1999-10-01	2009-12-15	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
US7592304B2 (en)	1999-10-01	2009-09-22	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
EP1224285A4 (en) *	1999-10-29	2004-12-08	Human Genome Sciences Inc	27 human secreted proteins
EP1235845A4 (en) *	1999-11-05	2003-06-25	Human Genome Sciences Inc	24 human secreted proteins
EP1237901A4 (en) *	1999-11-05	2005-01-12	Human Genome Sciences Inc	28 human secreted proteins
CA2389724A1 (en) *	1999-11-12	2001-05-17	Human Genome Sciences, Inc.	28 human secreted proteins
ES2629683T3 (en)	1999-11-30	2017-08-14	Mayo Foundation For Medical Education And Research	B7-H1, a new immunoregulatory molecule
DE60041564D1 (en)	1999-12-24	2009-03-26	Genentech Inc	Methods and compositions for extending the disposal half-life of bioactive compounds
US7534417B2 (en)	2000-02-24	2009-05-19	Agensys, Inc.	103P2D6: tissue specific protein highly expressed in various cancers
US7291122B2 (en) *	2000-03-24	2007-11-06	Immunocept, L.L.C.	Hemofiltration methods for treatment of diseases in a mammal
US20050100991A1 (en) *	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
ES2484966T3 (en) *	2000-04-12	2014-08-12	Novozymes Biopharma Dk A/S	Albumin fusion proteins
US7030219B2 (en) *	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
WO2001085936A1 (en) *	2000-05-12	2001-11-15	Merck Patent Gmbh	F-box containing protein
US6787040B2 (en) *	2000-05-16	2004-09-07	Immunocept, L.L.C.	Method and system for colloid exchange therapy
AU2001274923A1 (en) *	2000-05-23	2001-12-03	Lexicon Genetics Incorporated	Novel human thrombospondin-like proteins and polynucleotides encoding the same
CA2412377A1 (en)	2000-06-06	2001-12-13	Bristol-Myers Squibb Company	B7-related nucleic acids and polypeptides and their uses for immunomodulation
JP2004500862A (en) *	2000-06-08	2004-01-15	インサイト・ゲノミックス・インコーポレイテッド	Intracellular signaling protein
EP1294871A1 (en) *	2000-06-21	2003-03-26	Amgen, Inc.	Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof
AU2001229507A1 (en) *	2000-08-18	2002-03-04	Human Genome Sciences, Inc.	21 human secreted proteins
CA2418680A1 (en) *	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	11 human secreted proteins
EP1313761A4 (en) *	2000-08-28	2005-01-26	Human Genome Sciences Inc	18 human secreted proteins
EP1322659A4 (en) *	2000-09-20	2005-01-26	Human Genome Sciences Inc	21 human secreted proteins
AU2001227920A1 (en) *	2000-09-29	2002-04-15	Human Genome Sciences, Inc.	24 human secreted proteins
WO2002031111A2 (en) *	2000-10-12	2002-04-18	Hyseq, Inc.	Novel nucleic acids and polypeptides
US6531297B2 (en) *	2000-10-20	2003-03-11	Applera Corporation	Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
US6949371B2 (en)	2000-10-20	2005-09-27	Applera Corporation	Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
FR2815964A1 (en) *	2000-10-30	2002-05-03	Inst Nat Sante Rech Med	RENIN AND / OR PRORENIN RECEPTOR PROTEIN, NUCLEIC ACID ENCODING THE RECEPTOR AND THEIR APPLICATIONS
US6855493B2 (en)	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2002239229A1 (en) *	2000-12-05	2002-06-18	Wisconsin Alumni Research Foundation	Receptor for b. anthracis toxin
JP2004528014A (en)	2000-12-07	2004-09-16	イーライ・リリー・アンド・カンパニー	GLP-1 fusion protein
US20030148920A1 (en) *	2000-12-27	2003-08-07	Steven Rosen	Sulfatases and methods of use thereof
JP4344519B2 (en) *	2000-12-28	2009-10-14	旭化成ファーマ株式会社	NF-κB activating gene
CA2441006A1 (en) *	2001-03-08	2002-09-19	Hyseq, Inc.	Methods and materials relating to fibulin-like polypeptides and polynucleotides
AU2002318112B2 (en)	2001-04-10	2007-12-06	Agensys, Inc.	Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20050244931A1 (en) *	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060084794A1 (en) *	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US7507413B2 (en) *	2001-04-12	2009-03-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US20030100497A1 (en)	2001-06-20	2003-05-29	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP1405077A2 (en) *	2001-07-06	2004-04-07	Geneprot, Inc.	Carcinoma-related peptides
US7176278B2 (en)	2001-08-30	2007-02-13	Biorexis Technology, Inc.	Modified transferrin fusion proteins
US8129504B2 (en)	2001-08-30	2012-03-06	Biorexis Technology, Inc.	Oral delivery of modified transferrin fusion proteins
WO2003030821A2 (en) *	2001-10-05	2003-04-17	Human Genome Sciences, Inc.	Albumin fusion proteins
DE10251673A1 (en)	2001-11-09	2003-07-10	Hoffmann La Roche	Alström syndrome gene, gene variants, encoded protein and method for diagnosing Alström syndrome
KR100406760B1 (en) *	2001-11-16	2003-11-21	신코엠 주식회사	Semiconductor memory device
WO2003051921A1 (en)	2001-12-17	2003-06-26	Applied Research Systems Ars Holding N.V.	Chemokine mutants acting as chemokine antagonists
US20040082761A1 (en) *	2001-12-18	2004-04-29	Duggan Brendan M.	Cell adhesion proteins
US20080194481A1 (en) *	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
EP2277888A3 (en) *	2001-12-21	2011-04-27	Human Genome Sciences, Inc.	Fusion proteins of albumin and erythropoietin
KR101271635B1 (en) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	Albumin fusion proteins
WO2005003296A2 (en) *	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
AU2002364587A1 (en) *	2001-12-21	2003-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060253913A1 (en) *	2001-12-21	2006-11-09	Yue-Jin Huang	Production of hSA-linked butyrylcholinesterases in transgenic mammals
US7081446B2 (en) *	2002-01-31	2006-07-25	The Trustees Of Columbia University In The City Of New York	Long-acting follicle stimulating hormone analogues and uses thereof
US20060241027A1 (en) *	2002-02-07	2006-10-26	Hans-Peter Hauser	Hiv inhibiting proteins
ZA200406124B (en) *	2002-02-07	2008-09-25	Delta Biotechnology Ltd	Albumin-fused kunitz domain peptides
US20050222023A1 (en) *	2002-02-07	2005-10-06	Hans-Peter Hauser	Albumin-fused kunitz domain peptides
DE10205520A1 (en) *	2002-02-08	2003-08-14	Aventis Behring Gmbh	Inhibitory, monoclonal antibody against the clotting factor VII activating protease
PL374966A1 (en) *	2002-02-21	2005-11-14	Wyeth	Follistatin domain containing proteins
US20050169839A1 (en) *	2002-03-05	2005-08-04	Fong Tung M.	Biomarker for efficacy of appetite suppressant drugs
US20030191056A1 (en)	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US7217507B2 (en) *	2002-04-15	2007-05-15	The American National Red Cross	Method for detecting ligands and targets in a mixture
US20070015230A1 (en) *	2002-04-15	2007-01-18	Hammond David J	Identification and characterization of analytes from whole blood
US7319138B2 (en)	2002-04-18	2008-01-15	The General Hospital Corporation	Human DRG11-Responsive Axonal Guidance and Outgrowth of Neurite (DRAGON) proteins and variants thereof
US7141381B2 (en)	2002-04-25	2006-11-28	Bristol-Myers Squibb Company	Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
GB0210464D0 (en) *	2002-05-08	2002-06-12	Svanborg Catharina	Therapeutic treatment
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
PT1531850E (en) *	2002-06-07	2012-05-07	Zymogenetics Inc	Use of il-21 and monoclonal antibody for treating solid cancers
DK2311432T3 (en)	2002-06-07	2015-02-02	Dyax Corp	Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US8029803B2 (en)	2002-06-20	2011-10-04	Paladin Labs, Inc.	Chimeric antigens for eliciting an immune response
CN1241946C (en) *	2002-07-01	2006-02-15	美国福源集团	Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells
CN101172091B (en) *	2007-09-25	2011-04-27	北京美福源生物医药科技有限公司	Preparation process and application of fusion protein skin care product containing human serum albumin and skin cell growth factor
AU2003245089A1 (en) *	2002-07-03	2004-01-23	Nexgen Biotechnologies, Inc.	Fusion polypeptide comprising epidermal growth factor and human serum albumin
AU2003247806B2 (en) *	2002-07-08	2009-11-12	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
EP1541586A4 (en) *	2002-07-22	2006-08-09	Astellas Pharma Inc	Novel gene associated with rheumatoid arthritis
GB0217033D0 (en)	2002-07-23	2002-08-28	Delta Biotechnology Ltd	Gene and polypeptide sequences
WO2004015113A2 (en) *	2002-08-07	2004-02-19	Delta Biotechnology Ltd.	Albumin-fused ciliary neurotrophic factor
CA2495459C (en) *	2002-08-13	2009-10-27	Arbios Technologies Inc.	Selective plasma exchange therapy
ES2395014T3 (en)	2002-08-28	2013-02-07	Dyax Corp.	Methods to preserve organs and tissues
CA2496834C (en) *	2002-09-06	2014-03-18	Alexion Pharmaceuticals, Inc.	Method of treatment of asthma using antibodies to complement component c5
US20050271660A1 (en)	2002-09-06	2005-12-08	Alexion Pharmaceuticals, Inc.	Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en)	2002-09-06	2016-08-16	Alexion Pharmaceuticals, Inc.	High concentration formulations of anti-C5 antibodies
EP1539959A2 (en) *	2002-09-18	2005-06-15	Centre Hospitalier de l'Université de Montréal (CHUM)	Ghrh analogues
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
DE10254601A1 (en)	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Gene products differentially expressed in tumors and their use
ATE401346T1 (en) *	2002-12-20	2008-08-15	Geneos Oy	ASTHMA SENSITIVITY LOCATION
EP1577322A4 (en) *	2002-12-26	2006-01-25	Takeda Pharmaceutical	NEW PROTEINS AND THEIR USE
NZ570201A (en) *	2003-02-11	2011-03-31	Shire Human Genetic Therapies	Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge)
JP2006521111A (en) *	2003-03-12	2006-09-21	バスジーンセラピューティクス，インコーポレイテッド	Polypeptide compounds for inhibiting angiogenesis and tumor growth and applications thereof
US7381410B2 (en) *	2003-03-12	2008-06-03	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
US20070041987A1 (en) *	2003-03-19	2007-02-22	Daniel Carter	Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development
AU2004226162A1 (en) *	2003-04-04	2004-10-14	Universite De Lausanne	Peptabody for cancer treatment
KR101224235B1 (en)	2003-04-11	2013-01-25	메디뮨 엘엘씨	Recombinant IL-9 Antibodies and Uses Thereof
WO2004094589A2 (en) *	2003-04-18	2004-11-04	Incyte Corporation	Secreted proteins
US20050079546A1 (en) *	2003-05-01	2005-04-14	Dasa Lipovsek	Serum albumin scaffold-based proteins and uses thereof
US6987270B2 (en)	2003-05-07	2006-01-17	General Electric Company	Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
EP1650302B1 (en) *	2003-06-30	2012-03-21	Nihon University	Protein capable of deposition onto extracellular matrix
CA2532250A1 (en)	2003-07-15	2005-02-03	Barros Research Institute	Compositions and methods for immunotherapy of cancer and infectious diseases
US8007805B2 (en) *	2003-08-08	2011-08-30	Paladin Labs, Inc.	Chimeric antigens for breaking host tolerance to foreign antigens
GB0320877D0 (en) *	2003-09-05	2003-10-08	Celltech R&D Ltd	A protein involved in carcinoma
ATE476448T1 (en)	2003-11-04	2010-08-15	Novartis Vaccines & Diagnostic	USE OF ANTAGONIST ANTI-CD40 ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES AND ORGAN TRANSPLANT REJECTION
EP1704164B1 (en) *	2003-12-03	2011-12-28	Kröz, Monika	Interleukin-11 fusion proteins
CN100379762C (en) *	2003-12-08	2008-04-09	中国人民解放军军事医学科学院生物工程研究所	Fusion protein of human serum albumin and interleukin 2 and its coding gene
US9050378B2 (en)	2003-12-10	2015-06-09	Board Of Regents, The University Of Texas System	N2S2 chelate-targeting ligand conjugates
US7371381B2 (en)	2003-12-12	2008-05-13	Amgen Inc.	Anti-galanin antibodies and uses thereof
GB0329722D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Modified plasmid and use thereof
US9057061B2 (en)	2003-12-23	2015-06-16	Novozymes Biopharma Dk A/S	Gene expression technique
GB0329681D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Gene expression technique
CA2551546A1 (en) *	2003-12-24	2005-07-07	Takeda Pharmaceutical Company Limited	Preventive/remedy for cancer
JP5010923B2 (en) *	2004-02-09	2012-08-29	ヒューマンジノームサイエンシーズ，インコーポレイテッド	Albumin fusion protein
SE0400489D0 (en) *	2004-02-27	2004-02-27	Biovitrum Ab	Therapeutic proteins
DE602005019540D1 (en) *	2004-03-03	2010-04-08	Evotec Neurosciences Gmbh	DIAGNOSTIC AND THERAPEUTIC USE OF THE MAL2 GENE AND PROTEIN IN NEURODEEGENERATIVE DISEASES
US20050201959A1 (en) *	2004-03-11	2005-09-15	Vvii Newco 2003, Inc.	Methods and compositions for altering skin coloration
EP1740047A2 (en) *	2004-03-11	2007-01-10	Kythera Biopharmaceuticals, Inc.	Compositions and methods for preventing and treating skin and hair conditions
KR20120123619A (en)	2004-03-12	2012-11-08	바스진 테라퓨틱스, 인크.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
JP2007532666A (en) *	2004-04-14	2007-11-15	アヴィリッドインコーポレーテッド	Composition using modified nuclease for viral nucleic acid and method for preventing and treating viral diseases
ES2347902T3 (en) *	2004-04-23	2010-11-22	Conjuchem Biotechnologies Inc. Canadian Corporation 4528590	SOLID PHASE FOR USE IN A PROCEDURE FOR PURIFICATION OF ALBUMINE CONJUGATES.
KR100599454B1 (en) *	2004-04-27	2006-07-12	재단법인서울대학교산학협력재단	New Uses of AIM3 to Act as Tumor Suppressor
DE102004024617A1 (en)	2004-05-18	2005-12-29	Ganymed Pharmaceuticals Ag	Differentially expressed in tumors gene products and their use
CA2568976A1 (en) *	2004-06-03	2005-12-22	Ciphergen Biosystems, Inc.	Biomarkers for peripheral artery disease
CA2578709C (en) *	2004-06-17	2010-06-15	Virun, Inc.	Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
AU2005275062A1 (en)	2004-07-14	2006-02-23	University Of Utah Research Foundation	Netrin-related compositions and uses
US20060068425A1 (en) *	2004-08-13	2006-03-30	Millennium Pharmaceuticals, Inc.	Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2006034292A2 (en)	2004-09-21	2006-03-30	Medimmune, Inc.	Antibodies against and methods for producing vaccines for respiratory syncytial virus
ES2529451T3 (en)	2004-09-23	2015-02-20	Vasgene Therapeutics, Inc.	Polypeptide compounds to inhibit angiogenesis and tumor growth
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20060078541A1 (en) *	2004-10-01	2006-04-13	Giles Brian C	Method and formula for stem cells' stimulation, targeting release, trafficking and homing
JP5303146B2 (en)	2004-10-06	2013-10-02	メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ	B7-H1 and methods for diagnosis, prognosis and treatment of cancer
WO2006042197A2 (en) *	2004-10-11	2006-04-20	The Board Of Trustees Of The Leland Standford Junior University	Use of del-1 in hair, bone and cartilage regeneration
ES2507094T3 (en) *	2004-10-25	2014-10-14	Immune System Key Ltd.	Thymus specific protein
KR100583350B1 (en) *	2004-11-03	2006-06-05	(주)넥스젠	Method for producing epithelial cell regeneration factor using a fusion protein containing FAS-1 domain
KR101173717B1 (en) *	2004-11-09	2012-08-13	아레스 트레이딩 에스.에이.	Method for purifying fsh
JP5855326B2 (en)	2005-01-06	2016-02-09	ノヴォノルディスクアー／エス	Anti-KIR combination therapy and method
US20060178301A1 (en) *	2005-02-04	2006-08-10	Mathias Jurs	Albumin-fused ciliary neurotrophic factor
CA2597924C (en)	2005-02-15	2018-10-02	Duke University	Anti-cd19 antibodies and uses in oncology
US20110230407A1 (en) *	2005-03-14	2011-09-22	Alexander Yuzhakov	Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
BRPI0609449A2 (en) *	2005-03-23	2010-04-06	Wyeth Corp	gdf-8 modulation agent detection
CA2601086A1 (en) *	2005-03-23	2006-10-12	Wyeth	Detection of an immune response to gdf-8 modulating agents
WO2006111524A2 (en)	2005-04-18	2006-10-26	Novo Nordisk A/S	Il-21 variants
US7833979B2 (en) *	2005-04-22	2010-11-16	Amgen Inc.	Toxin peptide therapeutic agents
DK1874821T3 (en)	2005-04-26	2013-07-08	Trion Pharma Gmbh	Combination of antibodies with glycocorticoids to treat cancer
US9345745B2 (en)	2005-04-29	2016-05-24	Bo Wang	Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en)	2005-04-29	2017-03-07	Peter C. Dowling	Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
WO2007052154A2 (en)	2005-04-29	2007-05-10	University Of Medicine And Dentistry Of New Jersey	Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
AU2006244445B2 (en)	2005-05-05	2013-04-18	Duke University	Anti-CD19 antibody therapy for autoimmune disease
JP2008546426A (en) *	2005-05-12	2008-12-25	ザイモジェネティクス，インコーポレイテッド	Method of using pHHLA2 to costimulate T cells
KR101514463B1 (en)	2005-06-08	2015-04-28	다나-파버 캔서 인스티튜트 인크.	Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
WO2007014167A2 (en) *	2005-07-22	2007-02-01	Five Prime Therapeutics, Inc.	Compositions for and methods of treating epithelial diseases with growth factors
US8323666B2 (en) *	2005-08-01	2012-12-04	Allergan, Inc.	Botulinum toxin compositions
SI2573114T1 (en)	2005-08-10	2016-08-31	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
SG155183A1 (en)	2005-08-26	2009-09-30	Ares Trading Sa	Process for the preparation of glycosylated interferon beta
US7713715B2 (en) *	2005-09-06	2010-05-11	University Of Tennessee Research Foundation	Method for diagnosing infections
US20090099031A1 (en) *	2005-09-27	2009-04-16	Stemmer Willem P	Genetic package and uses thereof
EP1929073A4 (en) *	2005-09-27	2010-03-10	Amunix Inc	PROTEIN PHARMACEUTICAL PRODUCTS AND USES THEREOF
US7855279B2 (en) *	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
US7846445B2 (en) *	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
JP2009509564A (en) *	2005-10-03	2009-03-12	アストラゼネカ・アクチエボラーグ	Fusion proteins with regulated plasma half-life
US8168592B2 (en) *	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
EP1790664A1 (en)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoclonal antibodies against claudin-18 for treatment of cancer
MX2008007140A (en) *	2005-12-09	2009-03-04	Seattle Genetics Inc	Methods of using cd40 binding agents.
US8604175B2 (en) *	2005-12-09	2013-12-10	Ares Trading S.A.	Method for purifying FSH or a FSH mutant
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2007071068A1 (en) *	2005-12-22	2007-06-28	Conjuchem Biotechnologies Inc.	Process for the production of preformed conjugates of albumin and a therapeutic agent
US20090215084A1 (en) *	2006-01-05	2009-08-27	Mayo Foundation For Medical Education And Research	B7-h1 and b7-h4 in cancer
US20100015642A1 (en) *	2006-01-05	2010-01-21	Kwon Eugene D	B7-h1 and survivin in cancer
WO2007084568A2 (en)	2006-01-17	2007-07-26	Health Research, Inc.	Heteroduplex tracking assay
EP1816201A1 (en) *	2006-02-06	2007-08-08	CSL Behring GmbH	Modified coagulation factor VIIa with extended half-life
WO2007097961A1 (en) *	2006-02-16	2007-08-30	Massachusetts Eye & Ear Infirmary	Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
EP2540741A1 (en)	2006-03-06	2013-01-02	Aeres Biomedical Limited	Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2738178A1 (en) *	2006-04-05	2014-06-04	AbbVie Biotechnology Ltd	Antibody purification
AU2007236280B2 (en) *	2006-04-11	2013-07-25	Csl Behring Gmbh	Method of increasing the in vivo recovery of therapeutic polypeptides
WO2007124361A2 (en) *	2006-04-20	2007-11-01	Mayo Foundation For Medical Education And Research	Soluble b7-h1
US8334365B2 (en)	2006-06-07	2012-12-18	Human Genome Sciences, Inc.	Albumin fusion proteins
EP1867660A1 (en)	2006-06-14	2007-12-19	CSL Behring GmbH	Proteolytically cleavable fusion protein comprising a blood coagulation factor
AU2013202566C1 (en) *	2006-06-14	2018-07-12	Csl Behring Gmbh	Proteolytically cleavable fusion protein comprising a blood coagulation factor
US7939632B2 (en)	2006-06-14	2011-05-10	Csl Behring Gmbh	Proteolytically cleavable fusion proteins with high molar specific activity
ES2889920T3 (en)	2006-06-14	2022-01-14	Csl Behring Gmbh	Proteolytically Cleavable Fusion Proteins with High Molar Specific Activity
CA2657277C (en) *	2006-07-13	2015-11-24	Upperton Limited	Process for preparing particles of proteinaceous material
ES2371495T3 (en)	2006-07-24	2012-01-03	Biorexis Pharmaceutical Corporation	EXENDINE FUSION PROTEINS.
EP2049661A4 (en) *	2006-08-04	2012-07-04	Pharmathene Inc	Long half-life recombinant butyrylcholinesterase
CN101578373A (en) *	2006-09-06	2009-11-11	费斯生物制药公司	Fusion peptide therapeutic compositions
MX2009002523A (en)	2006-09-08	2009-03-20	Ambrx Inc	Modified human plasma polypeptide or fc scaffolds and their uses.
US10925977B2 (en)	2006-10-05	2021-02-23	Ceil>Point, LLC	Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
WO2008088422A2 (en) *	2006-10-25	2008-07-24	Amgen Inc.	Toxin peptide therapeutic agents
WO2008049920A2 (en)	2006-10-26	2008-05-02	Novo Nordisk A/S	Il-21 variants
EP2083861A4 (en)	2006-11-07	2010-11-24	Merck Sharp & Dohme	Antagonists of pcsk9
AU2007331195A1 (en)	2006-12-12	2008-06-19	Biorexis Pharmaceutical Corporation	Transferrin fusion protein libraries
AU2007336242B2 (en)	2006-12-19	2012-08-30	Ablynx N.V.	Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2514767A1 (en)	2006-12-19	2012-10-24	Ablynx N.V.	Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
EP2097096B1 (en) *	2006-12-22	2017-05-31	CSL Behring GmbH	Modified coagulation factors with prolonged in vivo half-life
EP1935430A1 (en) *	2006-12-22	2008-06-25	CSL Behring GmbH	Modified coagulation factors with prolonged in vivo half-life
CA3034396C (en)	2007-01-30	2022-08-02	Epivax, Inc.	Regulatory t cell epitopes, compositions and uses thereof
DK2526962T3 (en) *	2007-02-12	2019-10-07	Csl Behring Gmbh	Therapeutic application of Kazal-type serine protease inhibitors
WO2008118386A2 (en)	2007-03-27	2008-10-02	Merck & Co., Inc.	Method for detecting autoprocessed, secreted pcsk9
AU2008247382B2 (en)	2007-05-07	2014-06-05	Medimmune, Llc	Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
KR101827179B1 (en)	2007-05-14	2018-02-07	아스트라제네카 아베	Medicament for reducing basophil levels
EP2738257A1 (en)	2007-05-22	2014-06-04	Amgen Inc.	Compositions and methods for producing bioactive fusion proteins
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
WO2009029342A2 (en)	2007-07-13	2009-03-05	The Johns Hopkins University	B7-dc variants
US20100268055A1 (en) *	2007-07-19	2010-10-21	Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University	Self-Anchoring MEMS Intrafascicular Neural Electrode
EP2185701A4 (en) *	2007-08-15	2011-03-02	Amunix Operating Inc	Compositions and methods for modifying properties of biologically active polypeptides
DK2195023T3 (en)	2007-08-29	2018-06-18	Sanofi Sa	HUMANIZED ANTI-CXCR5 ANTIBODIES, DERIVATIVES THEREOF AND THEIR USE
JP2009055838A (en) *	2007-08-31	2009-03-19	Nipro Corp	Fusion protein, gene related to fusion protein, vector, transformant and anti-inflammatory pharmaceutical composition
CN103880965B (en) *	2007-09-21	2018-02-16	加利福尼亚大学董事会	The interferon for being led target shows strong Apoptosis and antitumor activity
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
CA2701221A1 (en) *	2007-10-22	2009-04-30	Merck Serono S.A.	Method for purifying an fc-containing protein
WO2009053358A1 (en) *	2007-10-22	2009-04-30	Merck Serono S.A.	Method for purifying fc-fusion proteins
EP2225275A4 (en)	2007-11-28	2013-04-03	Medimmune Llc	Protein formulation
KR101620539B1 (en)	2007-12-21	2016-05-13	메디뮨 리미티드	-4 -4 -173binding members for interleukin-4 receptor alpha il-4r-173
US8092804B2 (en)	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20100311072A1 (en) *	2008-01-28	2010-12-09	Bristol-Myers Squibb Company	Fluorescence polarization binding assay for characterizing glucokinase ligands
AR070315A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
AR070316A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
WO2009111315A2 (en) *	2008-02-29	2009-09-11	Mayo Foundation For Medical Education And Research	Methods for reducing granulomatous inflammation
JP5020135B2 (en) *	2008-03-19	2012-09-05	ソニーモバイルコミュニケーションズ，エービー	Portable terminal device and computer program
JP5818681B2 (en)	2008-04-01	2015-11-18	ノボ・ノルデイスク・エー／エス	Insulin albumin conjugate
CN102056945A (en)	2008-04-07	2011-05-11	埃博灵克斯股份有限公司	Amino acid sequences directed against the Notch pathways and uses thereof
KR20110021832A (en)	2008-05-02	2011-03-04	노파르티스 아게	Improved fibronectin-based binding molecules and uses thereof
AU2013202564B2 (en) *	2008-06-24	2015-09-17	Csl Behring Gmbh	Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
KR101648734B1 (en) *	2008-06-24	2016-08-18	체에스엘 베링 게엠베하	Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
EP4074327A1 (en)	2008-06-27	2022-10-19	Duke University	Therapeutic agents comprising elastin-like peptides
CA2767331A1 (en) *	2008-07-10	2010-01-14	Angion Biomedica Corp.	Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
CA2731617A1 (en)	2008-07-22	2010-01-28	Maria Joao Saraiva	Amino acid sequences directed against multitarget scavenger receptors and polypeptides
SG10201405377XA (en)	2008-08-05	2014-12-30	Novartis Ag	Compositions and methods for antibodies targeting complement protein c5
JP5798919B2 (en)	2008-08-25	2015-10-21	アンプリミューン、インコーポレーテッドＡｍｐｌｉｍｍｕｎｅ，Ｉｎｃ．	Compositions and methods of use of PD-1 antagonists
US20110159023A1 (en) *	2008-08-25	2011-06-30	Solomon Langermann	Pd-1 antagonists and methods for treating infectious disease
CN102282172B (en)	2008-09-07	2014-02-19	台湾醣联生技医药股份有限公司	Anti-stretched type I glycosphingolipid antibody, derivatives and uses thereof
ES2719496T3 (en)	2008-11-12	2019-07-10	Medimmune Llc	Antibody formulation
WO2010059315A1 (en) *	2008-11-18	2010-05-27	Merrimack Pharmaceuticals, Inc.	Human serum albumin linkers and conjugates thereof
CA2744449C (en)	2008-11-28	2019-01-29	Emory University	Methods for the treatment of infections and tumors
HUE034832T2 (en) *	2008-12-09	2021-12-28	Hoffmann La Roche	Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010068526A1 (en)	2008-12-12	2010-06-17	Merck Sharp & Dohme Corp.	Pcsk9 immunoassay
CA2744235A1 (en)	2009-01-06	2010-07-15	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
JP5753095B2 (en)	2009-01-16	2015-07-22	テバファーマシューティカルインダストリーズリミテッド	Stable preparation of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
WO2010087927A2 (en)	2009-02-02	2010-08-05	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8680050B2 (en) *	2009-02-03	2014-03-25	Amunix Operating Inc.	Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) *	2009-02-03	2014-04-22	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
JP5843357B2 (en)	2009-02-03	2016-01-13	アムニクスオペレーティングインコーポレイテッド	Extended recombinant polypeptide and composition comprising extended recombinant polypeptide
KR101722961B1 (en)	2009-02-11	2017-04-04	알부메딕스 에이/에스	Albumin variants and conjugates
EP2432488A4 (en)	2009-03-20	2014-01-08	Amgen Inc	Selective and potent peptide inhibitors of kv1.3
WO2010128143A1 (en)	2009-05-07	2010-11-11	Novozymes Biopharma Dk A/S	Method of controlling o-linked glycosylation of antibodies
EP2258398A1 (en) *	2009-05-26	2010-12-08	Araclón Biotech, S. L.	Albumin-amyloid peptide conjugates and uses thereof
US11512326B2 (en) *	2009-05-26	2022-11-29	University Of Florida Research Foundation, Incorporated	Small angiotensin peptide expression system in mammalian cells
US9849188B2 (en)	2009-06-08	2017-12-26	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
EP2440228B8 (en) *	2009-06-08	2023-02-22	Amunix Operating Inc.	Glucose-regulating polypeptides and methods of making and using same
US8840889B2 (en)	2009-08-13	2014-09-23	The Johns Hopkins University	Methods of modulating immune function
WO2011020866A2 (en)	2009-08-20	2011-02-24	Csl Behring Gmbh	Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US20110202016A1 (en) *	2009-08-24	2011-08-18	Arsenal Medical, Inc.	Systems and methods relating to polymer foams
JP2013502458A (en) *	2009-08-24	2013-01-24	アムニクスオペレーティングインコーポレイテッド	Coagulation factor VII composition and methods of making and using the same
US10420862B2 (en)	2009-08-24	2019-09-24	Aresenal AAA, LLC.	In-situ forming foams for treatment of aneurysms
US9044580B2 (en)	2009-08-24	2015-06-02	Arsenal Medical, Inc.	In-situ forming foams with outer layer
US9173817B2 (en)	2009-08-24	2015-11-03	Arsenal Medical, Inc.	In situ forming hemostatic foam implants
US8451450B2 (en) *	2009-09-14	2013-05-28	Bio-Rad Laboratories, Inc.	Near real time optical phase conjugation
UY32917A (en)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	DLL-4 BINDING MOLECULES
US20110172398A1 (en)	2009-10-02	2011-07-14	Boehringer Ingelheim International Gmbh	Bispecific binding molecules for anti-angiogenesis therapy
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
PL2486141T3 (en)	2009-10-07	2018-07-31	Macrogenics, Inc.	Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US20120322075A1 (en) *	2009-10-26	2012-12-20	Externautics S.P.A.	Lung Tumor Markers and Methods of Use Thereof
WO2011051327A2 (en)	2009-10-30	2011-05-05	Novartis Ag	Small antibody-like single chain proteins
US8748380B2 (en)	2009-10-30	2014-06-10	Novozymes Biopharma Dk A/S	Albumin variants
WO2011053759A1 (en)	2009-10-30	2011-05-05	Merck Sharp & Dohme Corp.	Ax1 and ax189 pcsk9 antagonists and variants
AU2010313324A1 (en)	2009-10-30	2012-04-12	Merck Sharp & Dohme Corp.	AX213 and AX132 PCSK9 antagonists and variants
WO2011051466A1 (en)	2009-11-02	2011-05-05	Novartis Ag	Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011060528A1 (en) *	2009-11-17	2011-05-26	Universite De Montreal	Heteropeptides useful for reducing nonspecific adsorption
MX353233B (en)	2009-12-06	2018-01-08	Bioverativ Therapeutics Inc	Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof.
AR079321A1 (en)	2009-12-08	2012-01-18	Teva Pharma	BUTIRILCOLINESTERASE ALBUMIN AND POLYPEPTIDE FUSIONS (BCHE) FOR THE TREATMENT OF COCAINE ABUSE
EP3309176B1 (en)	2009-12-14	2025-10-01	Ablynx N.V.	Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
AU2010340358B2 (en)	2009-12-21	2014-07-24	Pharmathene, Inc.	Recombinant butyrylcholinesterases and truncates thereof
ES2688093T3 (en)	2010-01-06	2018-10-30	Dyax Corp.	Plasma kallikrein binding proteins
AR079944A1 (en)	2010-01-20	2012-02-29	Boehringer Ingelheim Int	NEUTRALIZING ANTIBODY OF THE ACTIVITY OF AN ANTICOAGULANT
AU2011208620B2 (en)	2010-01-22	2015-04-16	Novo Nordisk Health Care Ag	Stable growth hormone compounds
TWI508737B (en)	2010-01-22	2015-11-21	諾佛儂迪克股份有限公司	Growth hormones with prolonged in-vivo efficacy
WO2011092233A1 (en)	2010-01-29	2011-08-04	Novartis Ag	Yeast mating to produce high-affinity combinations of fibronectin-based binders
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
US8592364B2 (en) *	2010-02-11	2013-11-26	Ecole Polytechnique Federale de Lausanne (“EPFL”)	CCR7 ligand delivery and co-delivery in immunotherapy
MX2012009460A (en)	2010-03-03	2012-09-12	Boehringer Ingelheim Int	Biparatopic abeta binding polypeptides.
EP2371857A1 (en)	2010-04-01	2011-10-05	CSL Behring GmbH	Factor XII inhibitors for treating interstitial lung disease
CN102939304B (en)	2010-04-09	2017-04-19	阿尔布麦狄克斯公司	albumin derivatives and variants
AU2011249782B2 (en)	2010-05-06	2014-10-02	Novartis Ag	Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
PH12012502406A1 (en)	2010-05-06	2013-02-18	Novartis Ag	Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MX2012013490A (en)	2010-05-20	2013-01-29	Ablynx Nv	BIOLOGICAL MATERIALS RELATED TO HER3.
SG186856A1 (en)	2010-07-09	2013-02-28	Biogen Idec Hemophilia Inc	Factor ix polypeptides and methods of use thereof
EP3508573A1 (en)	2010-07-09	2019-07-10	Bioverativ Therapeutics Inc.	Systems for factor viii processing and methods thereof
WO2012019061A2 (en)	2010-08-05	2012-02-09	Stem Centrx, Inc.	Novel effectors and methods of use
WO2012019168A2 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
US9850296B2 (en)	2010-08-10	2017-12-26	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
US9517257B2 (en)	2010-08-10	2016-12-13	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
JP6017422B2 (en)	2010-08-10	2016-11-02	エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）ＥｃｏｌｅＰｏｌｙｔｅｃｈｎｉｑｕｅＦｅｄｅｒａｌｅｄｅＬａｕｓａｎｎｅ（ＥＰＦＬ）	Erythrocyte binding therapy
SI2606070T1 (en)	2010-08-20	2017-04-26	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
RU2013113638A (en)	2010-08-27	2014-10-10	Стем Сентркс, Инк.	PROTEIN MODULATORS Notum AND WAYS OF THEIR APPLICATION
US20120225081A1 (en)	2010-09-03	2012-09-06	Boehringer Ingelheim International Gmbh	Vegf-binding molecules
BR112013005116A2 (en)	2010-09-03	2019-09-24	Stem Centrx Inc	modulators and methods of use
CA2885176C (en)	2010-09-22	2018-10-23	Amgen Inc.	Carrier immunoglobulins and uses thereof
DK2621519T3 (en)	2010-09-28	2017-10-16	Aegerion Pharmaceuticals Inc	Leptin-ABD fusion polypeptides with improved duration of action
EP3590949B1 (en)	2010-10-01	2022-05-18	ModernaTX, Inc.	Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
US8892184B2 (en)	2010-10-18	2014-11-18	Siemens Medical Solutions Usa, Inc.	Systems and methods for reducing interference in a dual modality imaging system
US8853490B2 (en) *	2010-10-26	2014-10-07	Pioneer Hi Bred International Inc	Antifungal proteins and methods of use
WO2012059486A1 (en)	2010-11-01	2012-05-10	Novozymes Biopharma Dk A/S	Albumin variants
US9562109B2 (en)	2010-11-05	2017-02-07	Zymeworks Inc.	Stable heterodimeric antibody design with mutations in the Fc domain
KR101650995B1 (en)	2010-11-08	2016-08-25	노파르티스 아게	Cxcr2 binding polypeptides
US9066974B1 (en)	2010-11-13	2015-06-30	Sirbal Ltd.	Molecular and herbal combinations for treating psoriasis
US9095606B1 (en)	2010-11-13	2015-08-04	Sirbal Ltd.	Molecular and herbal combinations for treating psoriasis
EP2643353A1 (en)	2010-11-24	2013-10-02	Novartis AG	Multispecific molecules
SG10201601792UA (en)	2010-12-08	2016-04-28	Stemcentrx Inc	Novel modulators and methods of use
US10393757B2 (en)	2010-12-28	2019-08-27	Dainippon Sumitomo Pharma Co., Ltd.	Diagnostic drug and diagnostic method for Alzheimer's disease
US20120171195A1 (en)	2011-01-03	2012-07-05	Ravindranath Mepur H	Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
KR102502293B1 (en)	2011-01-06	2023-02-21	다케다 파머수티컬 컴패니 리미티드	Plasma kallikrein binding proteins
SA112330278B1 (en)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	Novel modulators and methods of use
US20140105898A1 (en)	2011-02-28	2014-04-17	Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo	Apoptosis-inducing molecules and uses therefor
WO2012116453A1 (en)	2011-03-03	2012-09-07	Zymeworks Inc.	Multivalent heteromultimer scaffold design and constructs
ES2646191T3 (en)	2011-03-09	2017-12-12	Csl Behring Gmbh	Factor XII inhibitors for administration with medical procedures comprising contact with artificial surfaces
EP2497489A1 (en)	2011-03-09	2012-09-12	CSL Behring GmbH	Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
US20130344074A1 (en)	2011-03-16	2013-12-26	Sanofi	Uses of a dual v region antibody-like protein
HK1198173A1 (en)	2011-03-16	2015-03-13	Amgen Inc.	Potent and selective inhibitors of nav1.3 and nav1.7
WO2012135500A1 (en)	2011-03-29	2012-10-04	The General Hospital Corporation	Engineered thioredoxin-like fold proteins
KR20140009437A (en)	2011-03-30	2014-01-22	베링거 인겔하임 인터내셔날 게엠베하	Anticoagulant antidotes
AU2012236099A1 (en)	2011-03-31	2013-10-03	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
US20130078247A1 (en)	2011-04-01	2013-03-28	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
AU2012241373B2 (en)	2011-04-15	2016-06-09	Compugen Ltd.	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2515112B1 (en) *	2011-04-22	2015-08-12	Sysmex Corporation	Method for electrochemically detecting analyte
WO2012149197A2 (en)	2011-04-27	2012-11-01	Abbott Laboratories	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UA117218C2 (en)	2011-05-05	2018-07-10	Мерк Патент Гмбх	POLYPEPTIDE AGAINST IL-17A, IL-17F AND / OR IL17-A / F
KR20140027307A (en)	2011-05-05	2014-03-06	노보자임스 바이오파마 디케이 에이/에스	Albumin variants
US9561274B2 (en)	2011-06-07	2017-02-07	University Of Hawaii	Treatment and prevention of cancer with HMGB1 antagonists
WO2012170740A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
PL2717898T3 (en)	2011-06-10	2019-06-28	Bioverativ Therapeutics Inc.	Pro-coagulant compounds and methods of use thereof
WO2012172495A1 (en)	2011-06-14	2012-12-20	Novartis Ag	Compositions and methods for antibodies targeting tem8
US20160145589A1 (en)	2011-06-24	2016-05-26	Green Cross Corporation	Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
CA2839619C (en) *	2011-06-28	2021-11-16	Inhibrx Llc	Serpin fusion polypeptides and methods of use thereof
MX2014000031A (en)	2011-07-01	2014-07-09	Bayer Ip Gmbh	Relaxin fusion polypeptides and uses thereof.
JP6247210B2 (en)	2011-07-05	2017-12-13	アルブミディクスアクティーゼルスカブ	Albumin preparation and use
EP2729494A1 (en)	2011-07-08	2014-05-14	Bayer Intellectual Property GmbH	Fusion proteins releasing relaxin and uses thereof
WO2013009539A1 (en)	2011-07-08	2013-01-17	Amylin Pharmaceuticals, Inc.	Engineered polypeptides having enhanced duration of action and reduced immunogenicity
BR112014001274A2 (en) *	2011-07-18	2017-04-18	Arts Biologics As	luteinizing hormone compound and pharmaceutical composition
MX347454B (en)	2011-07-22	2017-04-27	Csl Ltd	Inhibitory anti -factor xii/xiia monoclonal antibodies and their uses.
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
RS62993B1 (en)	2011-10-03	2022-03-31	Modernatx Inc	Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2773373B1 (en)	2011-11-01	2018-08-22	Bionomics, Inc.	Methods of blocking cancer stem cell growth
US8993831B2 (en) *	2011-11-01	2015-03-31	Arsenal Medical, Inc.	Foam and delivery system for treatment of postpartum hemorrhage
AU2012332590B2 (en)	2011-11-01	2016-10-20	Bionomics, Inc.	Anti-GPR49 antibodies
US9221906B2 (en)	2011-11-01	2015-12-29	Bionomics Inc.	Methods of inhibiting solid tumor growth by administering GPR49 antibodies
EP2773667A1 (en)	2011-11-01	2014-09-10	Bionomics, Inc.	Anti-gpr49 antibodies
TW201323442A (en)	2011-11-04	2013-06-16	Novartis Ag	Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
CA2854233C (en)	2011-11-04	2020-05-12	Zymeworks Inc.	Stable heterodimeric antibody design with mutations in the fc domain
HK1200842A1 (en)	2011-11-18	2015-08-14	Albumedix Ltd	Proteins with improved half-life and other properties
CN104105709A (en)	2011-12-05	2014-10-15	诺华股份有限公司	Antibodies for epidermal growth factor receptor 3 (HER3) directed to domain II of HER3
WO2013084147A2 (en)	2011-12-05	2013-06-13	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
AU2012352180A1 (en)	2011-12-16	2014-07-31	Moderna Therapeutics, Inc.	Modified nucleoside, nucleotide, and nucleic acid compositions
SG10201703249PA (en)	2011-12-21	2017-05-30	Novartis Ag	Compositions and methods for antibodies targeting factor p
DK2793935T3 (en)	2011-12-22	2016-09-05	Csl Behring Gmbh	Use of C1 inhibitor in the treatment of secondary edema in the central nervous system.
US10800847B2 (en)	2012-01-11	2020-10-13	Dr. Mepur Ravindranath	Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20130177574A1 (en)	2012-01-11	2013-07-11	Paul I. Terasaki Foundation Laboratory	ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
KR102212098B1 (en)	2012-01-12	2021-02-03	바이오버라티브 테라퓨틱스 인크.	Chimeric factor viii polypeptides and uses thereof
EP2623110A1 (en)	2012-01-31	2013-08-07	CSL Behring GmbH	Factor XII inhibitors for the treatment of neurological inflammatory disorders
CN104271148A (en)	2012-02-15	2015-01-07	洛桑聚合联合学院	erythrocyte-binding therapeutics
EP2814502B1 (en) *	2012-02-15	2017-09-13	CSL Behring GmbH	Von willebrand factor variants having improved factor viii binding affinity
CA2864126A1 (en)	2012-02-15	2013-08-22	Biogen Idec Ma Inc.	Recombinant factor viii proteins
PT3564260T (en)	2012-02-15	2023-01-18	Bioverativ Therapeutics Inc	Factor viii compositions and methods of making and using same
BR112014020826A8 (en)	2012-02-24	2017-09-19	Stem Centrx Inc	ANTIBODY SPECIFICALLY BINDING TO AN Epitope, NUCLEIC ACID, VECTOR OR HOST CELL, DRUG CONJUGATE ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID ANTIBODY, USE THEREOF, KIT AND METHOD OF PREPARATION OF THE CONJUGATE
MX349192B (en)	2012-02-27	2017-07-18	Boehringer Ingelheim Int	Cx3cr1-binding polypeptides.
ES2664328T3 (en)	2012-03-16	2018-04-19	Albumedix A/S	Albumin variants
GB201204868D0 (en) *	2012-03-20	2012-05-02	San Raffaele Centro Fond	Peptides
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
EP2830646B1 (en)	2012-03-27	2018-03-07	NGM Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US10501512B2 (en)	2012-04-02	2019-12-10	Modernatx, Inc.	Modified polynucleotides
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
JP2015513912A (en)	2012-04-02	2015-05-18	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	Modified polynucleotides for the production of proteins
US9150645B2 (en)	2012-04-20	2015-10-06	Abbvie, Inc.	Cell culture methods to reduce acidic species
WO2013158273A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
BR112014026354A2 (en)	2012-04-27	2017-06-27	Cytomx Therapeutics Inc	activatable antibodies binding to epidermal growth factor receptor and methods of use thereof
WO2013166290A1 (en)	2012-05-04	2013-11-07	Abbvie Biotherapeutics Inc.	P21 biomarker assay
US9328174B2 (en)	2012-05-09	2016-05-03	Novartis Ag	Chemokine receptor binding polypeptides
WO2013167153A1 (en)	2012-05-09	2013-11-14	Ganymed Pharmaceuticals Ag	Antibodies useful in cancer diagnosis
CA2872540A1 (en)	2012-05-10	2013-11-14	Zymeworks Inc.	Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
WO2013177386A1 (en)	2012-05-24	2013-11-28	Abbvie Biotherapeutics Inc.	Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
PL2854552T3 (en)	2012-05-30	2019-11-29	Bayer Cropscience Ag	Composition comprising a biological control agent and a fungicide selected from inhibitors of amino acid or protein biosynthesis, inhibitors of atp production and inhibitors of the cell wall synthesis
EP2854529B1 (en)	2012-05-30	2018-01-17	Bayer Cropscience AG	Compositions comprising a biological control agent and an insecticide
AR091816A1 (en)	2012-05-30	2015-03-04	Bayer Cropscience Ag	COMPOSITION THAT INCLUDES A BIOLOGICAL CONTROL AGENT AND AN INSECTICIDE
JP2015519353A (en)	2012-05-30	2015-07-09	バイエル・クロップサイエンス・アーゲーＢａｙｅｒＣｒｏｐｓｃｉｅｎｃｅＡｇ	Composition containing biological control agent and insecticide
US9364006B2 (en)	2012-05-30	2016-06-14	Bayer Cropscience Ag	Composition comprising a biological control agent and a fungicide
KR102095976B1 (en)	2012-05-30	2020-04-02	바이엘 크롭사이언스 악티엔게젤샤프트	Compositions comprising a biological control agent and an insecticide
HUE040336T2 (en)	2012-05-30	2019-03-28	Bayer Cropscience Ag	Preparation containing a biological agent and fluopicolide
BR112014029553B1 (en)	2012-05-30	2019-11-26	Bayer Cropscience Ag	composition comprising a biological control agent and a fungicide, its uses, pathogen resistant seed, method for reducing total damage to plants and plant parts, and parts kit
EP3363289A3 (en)	2012-05-30	2018-10-17	Bayer CropScience Aktiengesellschaft	Compositions comprising a biological control agent and an insecticide
NZ742943A (en)	2012-05-30	2019-04-26	Bayer Cropscience Ag	Compositions comprising a biological control agent and a fungicide from the group consisting of inhibitors of the respiratory chain at complex i or ii
AR091197A1 (en)	2012-05-30	2015-01-21	Bayer Cropscience Ag	COMPOSITION THAT INCLUDES A BIOLOGICAL CONTROL AGENT AND A FUNGICIDE
WO2013178655A1 (en)	2012-05-30	2013-12-05	Bayer Cropscience Ag	Composition comprising a biological control agent and a fungicide selected from inhibitors of the lipid membrane synthesis, the melanine biosynthesis, the nucleic acid synthesis or the signal transduction
EP4079316A1 (en)	2012-06-08	2022-10-26	Bioverativ Therapeutics Inc.	Procoagulant compounds
US10202595B2 (en)	2012-06-08	2019-02-12	Bioverativ Therapeutics Inc.	Chimeric clotting factors
US9150841B2 (en)	2012-06-29	2015-10-06	Shire Human Genetic Therapies, Inc.	Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (en)	2012-06-29	2014-04-11	쉐어 휴먼 제네텍 세러피스, 인코포레이티드	Purification of iduronate-2-sulfatase
US10656156B2 (en)	2012-07-05	2020-05-19	Mepur Ravindranath	Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
PH12015500039B1 (en)	2012-07-11	2024-06-28	Bioverativ Therapeutics Inc	Factor viii complex with xten and von willebrand factor protein, and uses thereof
CN104768571B (en)	2012-07-13	2018-11-09	酵活有限公司	Multivalent heteromultimer scaffold design and constructs
WO2014036520A1 (en)	2012-08-30	2014-03-06	Merrimack Pharmaceuticals, Inc.	Combination therapies comprising anti-erbb3 agents
EP2890782A1 (en)	2012-09-02	2015-07-08	AbbVie Inc.	Methods to control protein heterogeneity
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
US10391152B2 (en)	2012-10-18	2019-08-27	Bioverativ Therapeutics Inc.	Methods of using a fixed dose of a clotting factor
BR112015010318A2 (en)	2012-11-08	2017-08-22	Albumedix As	ALBUMIN VARIANTS
RU2678127C2 (en)	2012-11-13	2019-01-23	Бионтех Аг	Agents for treatment of claudin expressing cancer diseases
PL2922554T3 (en)	2012-11-26	2022-06-20	Modernatx, Inc.	Terminally modified rna
WO2014084859A1 (en)	2012-11-30	2014-06-05	Novartis Ag	Molecules and methods for modulating tmem16a activities
AP2015008365A0 (en)	2012-12-05	2015-04-30	Novartis Ag	Compositions and methods for antibodies targeting epo
EP2935311B1 (en)	2012-12-20	2021-03-31	Amgen Inc.	Apj receptor agonists and uses thereof
EP2945703A4 (en)	2013-01-15	2016-08-31	Teva Pharma	Formulations of albu-bche, preparation and uses thereof
KR101503907B1 (en) *	2013-01-17	2015-03-20	서울대학교산학협력단	Recombinant protein vaccine for preventing Actinobacillus pleuropneumoniae and Mycoplasma hyopneumoniae infection diseases
US9161966B2 (en)	2013-01-30	2015-10-20	Ngm Biopharmaceuticals, Inc.	GDF15 mutein polypeptides
US9828415B2 (en)	2013-01-30	2017-11-28	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
TWI682941B (en)	2013-02-01	2020-01-21	美商再生元醫藥公司	Antibodies comprising chimeric constant domains
KR20150119022A (en)	2013-02-11	2015-10-23	바이엘 크롭사이언스 엘피	Compositions comprising gougerotin and a biological control agent
DK3889173T5 (en)	2013-02-15	2024-08-05	Bioverativ Therapeutics Inc	OPTIMIZED FACTOR VIII GENE
WO2014125082A1 (en)	2013-02-16	2014-08-21	Novozymes Biopharma Dk A/S	Pharmacokinetic animal model
WO2014131865A1 (en)	2013-02-28	2014-09-04	Csl Behring Gmbh	Therapeutic agent for amniotic fluid embolism
USRE48805E1 (en)	2013-03-06	2021-11-02	Vision Global Holdings Ltd.	Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
US9255262B2 (en) *	2013-03-06	2016-02-09	Vision Global Holdings Ltd.	Albumin-binding arginine deminase and the use thereof
ES2844189T3 (en)	2013-03-08	2021-07-21	Csl Behring Gmbh	Treatment and prevention of remote ischemia-reperfusion injuries
EP2968613B1 (en)	2013-03-11	2019-09-11	University of Florida Research Foundation, Inc.	Delivery of card protein as therapy for occular inflammation
CA2905010A1 (en)	2013-03-12	2014-09-18	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014165277A2 (en)	2013-03-12	2014-10-09	Amgen Inc.	POTENT AND SELECTIVE INHIBITORS OF Nav1.7
EP2968587A2 (en)	2013-03-13	2016-01-20	Bristol-Myers Squibb Company	Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
US20160024181A1 (en) *	2013-03-13	2016-01-28	Moderna Therapeutics, Inc.	Long-lived polynucleotide molecules
EP2970479B1 (en)	2013-03-14	2019-04-24	Novartis AG	Antibodies against notch 3
US8921526B2 (en)	2013-03-14	2014-12-30	Abbvie, Inc.	Mutated anti-TNFα antibodies and methods of their use
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en)	2013-03-14	2014-09-25	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
WO2014144549A1 (en)	2013-03-15	2014-09-18	Biogen Idec Ma Inc.	Factor ix polypeptide formulations
JP6505079B2 (en)	2013-03-29	2019-04-24	アレクシオンファーマシューティカルズ，インコーポレイテッド	Compositions and methods for increasing the serum half-life of a therapeutic that targets complement C5
WO2014166836A1 (en) *	2013-04-05	2014-10-16	Novo Nordisk A/S	Growth hormone compound formulation
ES2657291T3 (en)	2013-04-22	2018-03-02	Csl Ltd.	A covalent complex of von Willebrand factor and factor VIII associated by a disulfide bridge
AR096601A1 (en)	2013-06-21	2016-01-20	Novartis Ag	ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
US9562101B2 (en)	2013-06-21	2017-02-07	Novartis Ag	Lectin-like oxidized LDL receptor 1 antibodies and methods of use
MX2015016567A (en)	2013-06-28	2016-03-31	Biogen Ma Inc	Thrombin cleavable linker with xten and its uses thereof.
JP2017501968A (en)	2013-06-28	2017-01-19	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	Combination therapy using factor XII inhibitor and C1-inhibitor
CN104342420B (en) *	2013-07-30	2017-09-15	惠觅宙	A kind of recombinant long-acting people hyaluronidase, its encoding gene, production method and application
WO2015023894A1 (en)	2013-08-14	2015-02-19	Biogen Idec Ma Inc.	Recombinant factor viii proteins
TWI667255B (en)	2013-08-14	2019-08-01	美商生物化學醫療公司	Factor viii-xten fusions and uses thereof
WO2015026423A1 (en)	2013-08-20	2015-02-26	Infusion Medical, Inc.	Syringe fill system and method
PE20160674A1 (en)	2013-08-28	2016-07-21	Stemcentrx Inc	METHODS OF CONJUGATION OF SITE-SPECIFIC ANTIBODIES AND COMPOSITIONS
AU2014312310A1 (en)	2013-08-28	2016-04-07	Abbvie Stemcentrx Llc	Novel SEZ6 modulators and methods of use
HUE057005T2 (en)	2013-09-25	2022-04-28	Bioverativ Therapeutics Inc	Column virus inactivation procedures
CN103468662A (en) *	2013-09-29	2013-12-25	惠觅宙	Recombined human hyaluronidase, production and purification method and preparations thereof, use method and application
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
EP3470081A1 (en)	2013-10-01	2019-04-17	Mayo Foundation for Medical Education and Research	Methods for treating cancer in patients with elevated levels of bim
CN105980401A (en)	2013-10-03	2016-09-28	现代治疗公司	Polynucleotides encoding low density lipoprotein receptor
WO2015051293A2 (en)	2013-10-04	2015-04-09	Abbvie, Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057403A2 (en) *	2013-10-17	2015-04-23	Tarix Pharmaceuticals Ltd.	Compositions and methods for treatment of inflammatory bowel disease
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US9540440B2 (en)	2013-10-30	2017-01-10	Cytomx Therapeutics, Inc.	Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
SI3063275T1 (en)	2013-10-31	2020-02-28	Resolve Therapeutics, Llc	Therapeutic nuclease-albumin fusions and methods
US10208102B2 (en) *	2013-11-01	2019-02-19	University Of Oslo	Albumin variants and uses thereof
WO2015070014A1 (en)	2013-11-08	2015-05-14	Biogen Idec Ma Inc.	Procoagulant fusion compound
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
WO2015089283A1 (en)	2013-12-11	2015-06-18	Cytomx Therapeutics, Inc.	Antibodies that bind activatable antibodies and methods of use thereof
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
CA2935903A1 (en)	2014-01-09	2015-07-16	Hadasit Medical Research Services And Development Ltd.	Improved cell compositions and methods for cancer therapy
EP3091997B1 (en)	2014-01-10	2022-07-06	Bioverativ Therapeutics Inc.	Factor viii chimeric proteins and uses thereof
US10046056B2 (en)	2014-02-21	2018-08-14	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
US10946079B2 (en)	2014-02-21	2021-03-16	Ecole Polytechnique Federale De Lausanne	Glycotargeting therapeutics
EA201691686A1 (en)	2014-02-21	2017-03-31	Эколь Политекник Федераль Де Лозан (Эпфл)	THERAPEUTIC TOOLS WITH CARBOHYDRATE-MEDIATED ADDRESS DELIVERY
US10953101B2 (en)	2014-02-21	2021-03-23	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
EP3116898B1 (en)	2014-03-11	2022-01-26	University of Florida Research Foundation, Inc.	Aav-expressed m013 protein as an anti-inflammatroy therapeutic for use in a method of treating inflammatory ocular disease
US20170107294A1 (en) *	2014-03-21	2017-04-20	Nordlandssykehuset Hf	Anti-cd14 antibodies and uses thereof
WO2015160618A1 (en)	2014-04-16	2015-10-22	Bayer Cropscience Lp	Compositions comprising ningnanmycin and a biological control agent
WO2015164615A1 (en)	2014-04-24	2015-10-29	University Of Oslo	Anti-gluten antibodies and uses thereof
WO2015173633A2 (en)	2014-05-02	2015-11-19	Cerenis Therapeutics Holding Sa	Hdl therapy markers
US10302653B2 (en)	2014-05-22	2019-05-28	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti B7-H1 antibodies
CN105198999A (en) *	2014-05-27	2015-12-30	上海生物制品研究所有限责任公司	Fusion protein and its preparation method and use
USD774182S1 (en)	2014-06-06	2016-12-13	Anutra Medical, Inc.	Anesthetic delivery device
USD763433S1 (en)	2014-06-06	2016-08-09	Anutra Medical, Inc.	Delivery system cassette
USD750768S1 (en)	2014-06-06	2016-03-01	Anutra Medical, Inc.	Fluid administration syringe
MX370689B (en)	2014-06-10	2019-12-19	Amgen Inc	Apelin polypeptides.
EP3157548B1 (en)	2014-06-18	2021-08-04	CSL Behring GmbH	Therapy using a factor xii inhibitor in a neurotraumatic disorder
US20170204149A1 (en)	2014-06-23	2017-07-20	Novartis Ag	Hsa-gdf-15 fusion polypeptide and use thereof
BR112016029848A2 (en)	2014-06-24	2017-10-24	Novo Nordisk As	mic-1 fusion proteins and uses thereof
US11008561B2 (en)	2014-06-30	2021-05-18	Bioverativ Therapeutics Inc.	Optimized factor IX gene
US10517875B2 (en)	2014-07-23	2019-12-31	Mayo Foundation for Medical Engineering and Research	Targeting DNA-PKcs and B7-H1 to treat cancer
MX370115B (en)	2014-07-30	2019-12-02	Ngm Biopharmaceuticals Inc	Compositions and methods of use for treating metabolic disorders.
AP2017009721A0 (en)	2014-08-07	2017-01-31	Novartis Ag	Angiopoietin-like 4 antibodies and methods of use
EP3194437B1 (en)	2014-08-07	2021-01-20	Novartis AG	Angiopoietin-like 4 (angptl4) antibodies and methods of use
RU2685869C1 (en)	2014-08-22	2019-04-23	Нэшенл Ченг Кунг Юниверсити	Versions of disintegrin and their pharmaceutical application
RU2736827C2 (en)	2014-09-17	2020-11-20	Байер Кропсайенс Лп	Compositions containing bacillus recombinant cells and another biological control agent
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MX2017003897A (en)	2014-09-26	2017-06-28	Bayer Pharma AG	Stabilized adrenomedullin derivatives and use thereof.
MA41044A (en)	2014-10-08	2017-08-15	Novartis Ag	COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
DK3207130T3 (en)	2014-10-14	2019-11-11	Halozyme Inc	Compositions of Adenosine Deaminase-2 (ADA2), Variants thereof, and Methods for Using the Same
MA40835A (en)	2014-10-23	2017-08-29	Biogen Ma Inc	ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en)	2014-10-31	2017-09-05	Biogen Ma Inc	ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
MY186702A (en)	2014-10-31	2021-08-11	Ngm Biopharmaceuticals Inc	Compositions and methods of use for treating metabolic disorders
US20160130324A1 (en) *	2014-10-31	2016-05-12	Shire Human Genetic Therapies, Inc.	C1 Inhibitor Fusion Proteins and Uses Thereof
GB201420139D0 (en)	2014-11-12	2014-12-24	Ucl Business Plc	Factor IX gene therapy
UY36449A (en)	2014-12-19	2016-07-29	Novartis Ag	COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
EP3236939B2 (en) *	2014-12-23	2024-08-28	Merz Pharma GmbH & Co. KGaA	Botulinum toxin prefilled container
ES2846748T3 (en)	2015-03-30	2021-07-29	Regeneron Pharma	Heavy chain constant regions with reduced binding to Fc gamma receptors
JP2016204292A (en) *	2015-04-21	2016-12-08	国立大学法人熊本大学	Fusion of BMP7 mutant and albumin, and renal disease therapeutic agent containing the fusion
WO2016174575A1 (en) *	2015-04-29	2016-11-03	Mediolanum Farmaceutici S.P.A.	A soluble chimeric interleukin-10 receptor and therapeutic use thereof
US10676723B2 (en)	2015-05-11	2020-06-09	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
WO2016195723A1 (en) *	2015-06-03	2016-12-08	Beller Pharmaceuticals LLC	Methods of treatment for conditions mediated by substance p
CN107614526A (en)	2015-06-05	2018-01-19	诺华股份有限公司	Target the antibody and its method of BMP 9 (BMP9)
WO2016201202A1 (en) *	2015-06-11	2016-12-15	Attwill Medical Solutions Inc.	Medical devices, systems, and methods utilizing antithrombin-heparin compositions
JOP20200312A1 (en)	2015-06-26	2017-06-16	Novartis Ag	Factor xi antibodies and methods of use
CN107921096A (en) *	2015-07-30	2018-04-17	恩多技术公司	Colony-stimulating factor for pancreatic or colon cancer treatment
EA201890423A1 (en)	2015-08-03	2018-07-31	Биовератив Терапьютикс Инк.	SLIGHT PROTEINS OF THE FACTOR IX, METHODS OF THEIR RECEPTION AND APPLICATION
RU2752530C2 (en)	2015-08-03	2021-07-29	Новартис Аг	Methods for treating fgf21-related disorders
CA2994552A1 (en)	2015-08-06	2017-02-09	The Trustees Of The University Of Pennsylvania	Glucagon-like peptide 1 and use thereof in compositions for treating metabolic diseases
WO2017029407A1 (en)	2015-08-20	2017-02-23	Albumedix A/S	Albumin variants and conjugates
HRP20210635T1 (en)	2015-09-08	2021-08-20	Jcr Pharmaceuticals Co., Ltd.	NEW MUTANT OF HUMAN SERUM ALBUMIN
KR20180042433A (en)	2015-09-09	2018-04-25	노파르티스 아게	Use of thymus substrate lymphopoietin (TSLP) -binding antibodies and antibodies
WO2017042701A1 (en)	2015-09-09	2017-03-16	Novartis Ag	Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
HK1258138A1 (en)	2015-09-11	2019-11-08	The Board Of Trustees Of The Leland Stanford Junior University	Biologically relevant orthogonal cytokine/receptor pairs
WO2017075045A2 (en)	2015-10-30	2017-05-04	Mayo Foundation For Medical Education And Research	Antibodies to b7-h1
TWI734719B (en)	2015-12-04	2021-08-01	德商百靈佳殷格翰國際股份有限公司	Biparatopic polypeptides antagonizing wnt signaling in tumor cells
CA2994447A1 (en)	2015-12-11	2017-06-15	Dyax Corp.	Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
RU2018126297A (en)	2015-12-18	2020-01-22	Новартис Аг	ANTIBODIES AIMED AT CD32B AND WAYS TO USE THEM
US20190000923A1 (en)	2015-12-22	2019-01-03	Novartis Ag	Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EA039865B1 (en)	2016-01-11	2022-03-22	Универзитет Цюрих	Immune-stimulating humanized monoclonal antibody against human interleukin-2 and fusion protein
EP3405492B1 (en)	2016-01-21	2020-10-21	Novartis AG	Multispecific molecules targeting cll-1
AU2017214378B2 (en)	2016-02-01	2023-05-04	Bioverativ Therapeutics Inc.	Optimized Factor VIII genes
JP2017165713A (en)	2016-03-14	2017-09-21	Ｊｃｒファーマ株式会社	Serum albumin-20K growth hormone fusion protein
JP2019509322A (en)	2016-03-22	2019-04-04	バイオノミクスリミテッド	Administration of anti-LGR5 monoclonal antibody
PE20190126A1 (en)	2016-03-31	2019-01-17	Ngm Biopharmaceuticals Inc	BINDING PROTEINS AND METHODS OF USING THEM
EP3440107A4 (en)	2016-04-06	2020-02-19	CSL Limited	METHOD OF TREATING ATHEROSCLEROSIS
EP3448887A1 (en)	2016-04-27	2019-03-06	Novartis AG	Antibodies against growth differentiation factor 15 and uses thereof
IL262892B2 (en)	2016-05-18	2024-04-01	Boehringer Ingelheim Int	Anti-PD-1 and anti-LAG3 antibodies for cancer treatment
EP3463412A1 (en)	2016-05-24	2019-04-10	Novo Nordisk A/S	Mic-1 compounds and use thereof
AU2017283787B2 (en)	2016-06-15	2020-09-17	Novartis Ag	Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
ES2832648T3 (en) *	2016-07-08	2021-06-10	CSL Behring Lengnau AG	Subcutaneous Administration of Long-Acting Factor IX in Humans
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
US20190175683A1 (en)	2016-08-05	2019-06-13	Csl Behring Gmbh	Pharmaceutical formulations of c1 esterase inhibitor
EP3504648A1 (en)	2016-08-23	2019-07-03	CSL Behring GmbH	Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
WO2018082758A1 (en)	2016-11-04	2018-05-11	Aarhus Universitet	Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
WO2018091679A1 (en) *	2016-11-18	2018-05-24	Universitat De Barcelona	Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
WO2018096396A1 (en)	2016-11-22	2018-05-31	University Of Oslo	Albumin variants and uses thereof
EP3548063A1 (en)	2016-12-02	2019-10-09	Bioverativ Therapeutics Inc.	Methods of inducing immune tolerance to clotting factors
JP7748175B2 (en)	2016-12-02	2025-10-02	バイオベラティブセラピューティクスインコーポレイテッド	Methods for treating hemophilic arthropathy using chimeric clotting factors - Patent Application 20070122999
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
MA47163A (en)	2016-12-16	2019-11-06	Biogen Ma Inc	PROTEOLYTICALLY STABILIZED ACTIVATED GROWTH DIFFERENTIATION FACTOR 11
EP3360898A1 (en)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
CN118320078A (en)	2016-12-23	2024-07-12	诺华股份有限公司	Methods of treatment using anti-factor XI/XIa antibodies
WO2018119354A1 (en)	2016-12-23	2018-06-28	President And Fellows Of Harvard College	Gene editing of pcsk9
JP7139332B2 (en)	2016-12-23	2022-09-20	ノバルティスアーゲー	Factor XI Antibodies and Methods of Use
WO2018132768A1 (en)	2017-01-13	2018-07-19	Sanna Pietro P	Methods and compositions for treating hpa hyperactivity
BR112019015569A2 (en)	2017-01-31	2020-03-17	Bioverativ Therapeutics Inc.	FACTOR IX FUSION PROTEINS AND METHODS FOR THEIR PRODUCTION AND USE
BR112019016344A2 (en)	2017-02-08	2020-04-07	Novartis Ag	mimetic antibodies fgf21 and uses thereof
US10767164B2 (en)	2017-03-30	2020-09-08	The Research Foundation For The State University Of New York	Microenvironments for self-assembly of islet organoids from stem cells differentiation
JP2020517657A (en)	2017-04-20	2020-06-18	ノヴォノルディスクアー／エス	Purification method of albumin fusion protein
TWI710377B (en)	2017-05-23	2020-11-21	丹麥商諾佛儂迪克股份有限公司	Mic-1 compounds and uses thereof
AU2018274216A1 (en)	2017-05-24	2019-12-12	Novartis Ag	Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
US11033636B2 (en)	2017-05-31	2021-06-15	Boehringer Ingelheim International Gmbh	Polypeptides antagonizing Wnt signaling in tumor cells
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
US11253579B2 (en)	2017-06-16	2022-02-22	The University Of Chicago	Compositions and methods for inducing immune tolerance
US20200115436A1 (en)	2017-06-29	2020-04-16	CSL Behring Lengnau AG	21-day dosing regimen for fusion proteins comprising factor ix and human albumin for prophylactic treatment of hemophilia and methods thereof
MA68842B1 (en)	2017-08-04	2025-01-31	Amgen Inc.	CYS-MABS CONJUGATION PROCESS
BR112020002394A2 (en)	2017-08-09	2020-07-28	Bioverativ Therapeutics Inc.	nucleic acid molecules and uses thereof
EP3684811A2 (en)	2017-08-17	2020-07-29	Massachusetts Institute of Technology	Multiple specificity binders of cxc chemokines and uses thereof
US12059456B2 (en)	2017-09-15	2024-08-13	Cedars-Sinai Medical Center	Methods of using C1 esterase inhibitor for improving early onset and long-term function of kidney transplants from grafts associated with delayed graft function
EP3697812A4 (en)	2017-10-18	2021-09-22	CSL Limited	HUMAN SERIAL ALBUMIN VARIANTS AND THEIR USES
EP3700933A1 (en)	2017-10-25	2020-09-02	Novartis AG	Antibodies targeting cd32b and methods of use thereof
CA3085478A1 (en)	2017-12-15	2019-06-20	Csl Limited	Use of a fxiia-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
WO2019129054A1 (en)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	Triabody, preparation method and use thereof
WO2019129221A1 (en)	2017-12-28	2019-07-04	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against tigit
US11246908B2 (en) *	2018-01-10	2022-02-15	The Johns Hopkins University	Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
EP3740507A4 (en)	2018-01-15	2022-08-24	Nanjing Legend Biotech Co., Ltd.	SINGLE-DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
WO2019152692A1 (en)	2018-02-01	2019-08-08	Bioverativ Therapeutics, Inc.	Use of lentiviral vectors expressing factor viii
AU2019233613B2 (en) *	2018-03-13	2025-02-13	Sepsia Therapeutics, S.L.	Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes
BR112020018618A2 (en)	2018-03-13	2020-12-29	Zymeworks, Inc.	ANTI-HER2 BIPARATOPIC-DRUG ANTIBODY CONJUGATES AND METHODS OF USE
CN112154153B (en)	2018-03-28	2025-05-23	百时美施贵宝公司	Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
US11958903B2 (en)	2018-03-30	2024-04-16	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies against LAG-3 and uses thereof
KR102119197B1 (en) *	2018-04-23	2020-06-05	주식회사 엘베이스	Composition for autophagy inhibiting in cell, And pharmaceutical composition for preventing or treating tumor disease, or inhibiting anti-cancer agents resistance containing the same
IL278538B2 (en)	2018-05-09	2024-01-01	Univ Chicago	Compositions and methods relating to immune tolerance
IL322964A (en)	2018-05-14	2025-10-01	Werewolf Therapeutics Inc	Activatable interleukin 12 polypeptides and methods of use thereof
FI3794024T3 (en)	2018-05-14	2023-08-10	Werewolf Therapeutics Inc	ACTIVATING INTERLEUKIN-2 POLYPEPTIDES AND THEIR METHODS OF USE
CN112512555A (en)	2018-05-18	2021-03-16	比奥维拉迪维治疗股份有限公司	How to treat hemophilia A
EP3569618A1 (en)	2018-05-19	2019-11-20	Boehringer Ingelheim International GmbH	Antagonizing cd73 antibody
TWI869346B (en)	2018-05-30	2025-01-11	瑞士商諾華公司	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
IL317554A (en)	2018-06-01	2025-02-01	Novartis Ag	Binding molecules against bcma and uses thereof
CN112368015B (en)	2018-06-18	2025-04-29	安维达生物科技公司	Cytokine fusion protein and its use
MX2021000016A (en)	2018-07-03	2021-03-09	Bristol Myers Squibb Co	Fgf21 formulations.
JP7602454B2 (en)	2018-08-09	2024-12-18	バイオベラティブセラピューティクスインコーポレイテッド	Nucleic Acid Molecules and Their Use for Non-Viral Gene Therapy - Patent application
US10842885B2 (en)	2018-08-20	2020-11-24	Ucl Business Ltd	Factor IX encoding nucleotides
GB201813528D0 (en)	2018-08-20	2018-10-03	Ucl Business Plc	Factor IX encoding nucleotides
PL3844189T3 (en)	2018-08-31	2025-03-31	Regeneron Pharmaceuticals, Inc.	Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
JP2022500427A (en) *	2018-09-17	2022-01-04	国立大学法人京都大学	Administration of anti-C5 agents for the treatment of liver injury or liver failure
EP3856764A4 (en)	2018-09-27	2022-11-02	Xilio Development, Inc.	MASKED CYTOKINE POLYPEPTIDES
US12331320B2 (en)	2018-10-10	2025-06-17	The Research Foundation For The State University Of New York	Genome edited cancer cell vaccines
UY38407A (en)	2018-10-15	2020-05-29	Novartis Ag	TREM2 STABILIZING ANTIBODIES
AU2019369403B2 (en) *	2018-10-29	2025-04-17	Spin Therapeutics, Llc	Compositions and methods for alpha-1-antitrypsin disorders
EP3873500A4 (en)	2018-10-31	2023-01-11	Mayo Foundation for Medical Education and Research	CANCER TREATMENT METHODS AND MATERIALS
GB201818477D0 (en)	2018-11-13	2018-12-26	Emstopa Ltd	Tissue plasminogen activator antibodies and method of use thereof
CN113396158A (en)	2018-11-26	2021-09-14	诺华股份有限公司	LPL-GPIHBP1 fusion polypeptide
WO2020118069A2 (en)	2018-12-06	2020-06-11	Bioverativ Therapeutics Inc.	Use of lentiviral vectors expressing factor ix
WO2020198075A2 (en)	2019-03-22	2020-10-01	Reflexion Pharmaceuticals, Inc.	Multivalent d-peptidic compounds for target proteins
CN119930814A (en)	2019-03-22	2025-05-06	反射制药有限公司	D-peptide compounds targeting VEGF
WO2020198731A2 (en)	2019-03-28	2020-10-01	Danisco Us Inc	Engineered antibodies
BR112021020367A2 (en)	2019-04-11	2021-12-07	Angion Biomedica Corp	Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole
CA3137512A1 (en)	2019-05-14	2020-11-19	Werewolf Therapeutics, Inc.	Separation moieties and methods and use thereof
EP3972993A1 (en)	2019-05-21	2022-03-30	Novartis AG	Variant cd58 domains and uses thereof
CN121293351A (en)	2019-05-21	2026-01-09	诺华股份有限公司	CD19 binding molecules and uses thereof
KR20220012894A (en)	2019-05-24	2022-02-04	사노피	How to treat systemic sclerosis
CN114174326A (en)	2019-06-18	2022-03-11	拜耳公司	Long-term stable adrenomedullin analogues and uses thereof
WO2021044361A1 (en)	2019-09-06	2021-03-11	Novartis Ag	Therapeutic fusion proteins
WO2021053559A1 (en)	2019-09-18	2021-03-25	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (en)	2019-09-18	2021-07-01	瑞士商諾華公司	Combination therapies with entpd2 antibodies
TW202126284A (en)	2019-09-30	2021-07-16	美商百歐維拉提夫治療公司	Lentiviral vector formulations
JP2021066730A (en)	2019-10-17	2021-04-30	Ｊｃｒファーマ株式会社	Method for producing fusion protein of serum albumin and growth hormone
US20220378882A1 (en)	2019-10-30	2022-12-01	Jcr Pharmaceuticals Co., Ltd.	Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone
CA3155981A1 (en)	2019-11-14	2021-05-20	William Winston	Activatable cytokine polypeptides and methods of use thereof
EP4069200A1 (en)	2019-12-04	2022-10-12	Albumedix Ltd	Methods and compositions produced thereby
BR112022011513A2 (en)	2019-12-13	2022-08-23	Synthekine Inc	IL-2 ORTHHOLOGS AND METHODS OF USE
US20210181200A1 (en) *	2019-12-17	2021-06-17	Women's College Hospital	Ovarian cancer biomarker and methods of using same
JP2023512423A (en)	2019-12-24	2023-03-27	ジュベナ・セラピューティクス・インコーポレイテッド	Regenerative polypeptides and uses thereof
WO2021146160A1 (en)	2020-01-13	2021-07-22	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
WO2021202473A2 (en)	2020-03-30	2021-10-07	Danisco Us Inc	Engineered antibodies
EP4133072A4 (en)	2020-04-09	2024-11-06	Verve Therapeutics, Inc.	CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9
PH12022553153A1 (en)	2020-05-19	2024-02-26	Boehringer Ingelheim Int	Binding molecules for the treatment of cancer
AU2021293174A1 (en)	2020-06-14	2023-01-19	Vertex Pharmaceuticals Incorporated	Complement Factor I-related compositions and methods
KR20230074703A (en)	2020-06-24	2023-05-31	바이오버라티브 테라퓨틱스 인크.	Method for removing free factor VIII from preparations of lentiviral vectors modified to express the protein
WO2022084354A1 (en)	2020-10-21	2022-04-28	Boehringer Ingelheim International Gmbh	Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases
US20230390364A1 (en) *	2020-10-30	2023-12-07	Shenzhen Protgen Ltd.	Use of human serum albumin in treatment of diseases
IL302569A (en)	2020-11-06	2023-07-01	Novartis Ag	CD19 binding molecules and their uses
KR20230113581A (en)	2020-11-25	2023-07-31	실리오 디벨럽먼트, 인크.	Tumor-specific cleavable linkers
CN114478800B (en) *	2021-02-05	2022-10-11	华南理工大学	Fusion protein based on serum albumin, nano assembly, preparation method and application thereof
CA3209052A1 (en)	2021-02-19	2022-08-25	Rafael Cristian CASELLAS	Single domain antibodies that neutralize sars-cov-2
CN117957256A (en)	2021-06-17	2024-04-30	勃林格殷格翰国际有限公司	Novel trispecific binding molecules
KR20240029031A (en) *	2021-06-21	2024-03-05	쥬베나 테라퓨틱스, 인크.	Regenerative polypeptides and uses thereof
CN114133458B (en) *	2021-12-08	2023-11-14	福州大学	A method for fusing polypeptides within human serum albumin
IL316174A (en)	2022-04-26	2024-12-01	Novartis Ag	Multispecific antibodies targeting il-13 and il-18
CN119546339A (en)	2022-07-15	2025-02-28	丹尼斯科美国公司	Methods for producing monoclonal antibodies
MA71446A (en)	2022-07-15	2025-04-30	Boehringer Ingelheim International Gmbh	BINDING MOLECULES FOR CANCER TREATMENT
EP4605077A1 (en)	2022-10-18	2025-08-27	Confo Therapeutics N.V.	Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024130158A1 (en)	2022-12-16	2024-06-20	Modernatx, Inc.	Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
KR20250124838A (en) *	2022-12-20	2025-08-20	씨에스엘 이노베이션 피티와이 엘티디	FcRn antagonists and uses thereof
EP4389762A1 (en)	2022-12-23	2024-06-26	Ospedale San Raffaele S.r.l.	Inhibitors of dux4 activity and their use in therapy.
WO2024178305A1 (en)	2023-02-24	2024-08-29	Modernatx, Inc.	Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
EP4442251A1 (en)	2023-04-05	2024-10-09	Albumedix Ltd	Formulations and uses thereof
WO2025034806A1 (en)	2023-08-08	2025-02-13	Wisconsin Alumni Research Foundation	Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025072888A2 (en)	2023-09-28	2025-04-03	Novavax, Inc.	Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19

Family Cites Families (702)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5625041A (en) *	1990-09-12	1997-04-29	Delta Biotechnology Limited	Purification of proteins
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
DE2449885C3 (en) *	1974-10-21	1980-04-30	Biotest-Serum-Institut Gmbh, 6000 Frankfurt	Process for the production of chemically modified, long-life hemoglobin preparations as well as the modified hemoglobin preparation produced by this process
US4002531A (en)	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US4440859A (en) *	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4264731A (en) *	1977-05-27	1981-04-28	The Regents Of The University Of California	DNA Joining method
US4363877B1 (en)	1977-09-23	1998-05-26	Univ California	Recombinant dna transfer vectors
US4283489A (en)	1977-09-23	1981-08-11	The Regents Of The University Of California	Purification of nucleotide sequences suitable for expression in bacteria
US4407948A (en)	1977-09-23	1983-10-04	The Regents Of The University Of California	Purification of nucleotide sequences suitable for expression in bacteria
US4366246A (en)	1977-11-08	1982-12-28	Genentech, Inc.	Method for microbial polypeptide expression
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4447538A (en) *	1978-04-19	1984-05-08	Regents Of The University Of California	Microorganism containing gene for human chorionic somatomammotropin
US4652525A (en) *	1978-04-19	1987-03-24	The Regents Of The University Of California	Recombinant bacterial plasmids containing the coding sequences of insulin genes
US5514567A (en) *	1979-01-30	1996-05-07	Juridical Foundation, Japanese Foundation For Cancer Research	DNA and recombinant plasmid
US5326859A (en)	1979-10-30	1994-07-05	Juridical Foundation, Japanese Foundation For Cancer Research	DNA and recombinant plasmid
US4342832A (en)	1979-07-05	1982-08-03	Genentech, Inc.	Method of constructing a replicable cloning vehicle having quasi-synthetic genes
AU538665B2 (en)	1979-10-30	1984-08-23	Juridical Foundation, Japanese Foundation For Cancer Research	Human interferon dna
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
AU553400B2 (en)	1980-01-08	1986-07-17	Biogen, Inc.	Recombinant dna for producing interferon
CA1341604C (en)	1980-04-03	2010-05-04	Biogen N.V.	Dna sequences, recombinant dna molecules and processes for producing human fibroblast interferon-like polypeptides
DE3023787A1 (en)	1980-06-25	1982-01-21	Studiengesellschaft Kohle mbH, 4330 Mülheim	METHOD FOR INCREASING THE INCORPORATION AND EXPRESSION OF GENETIC MATERIAL IN THE CORE OF INTACT CELLS BY LIPOSOME
US6610830B1 (en)	1980-07-01	2003-08-26	Hoffman-La Roche Inc.	Microbial production of mature human leukocyte interferons
NZ198445A (en)	1980-09-25	1984-05-31	Genentech Inc	Production of human fibroblast interferon by recombinant dna technology
ATE12348T1 (en)	1980-11-10	1985-04-15	Gersonde Klaus Prof Dr	PROCESS FOR THE PRODUCTION OF LIPID VESICLES BY ULTRASONIC TREATMENT, APPLICATION OF THE PROCESS AND DEVICE FOR CARRYING OUT THE PROCESS.
US4456748A (en)	1981-02-23	1984-06-26	Genentech, Inc.	Hybrid human leukocyte interferons
EP0070906B1 (en)	1981-02-04	1986-10-15	Juridical Foundation Japanese Foundation For Cancer Research	Human interferon-beta gene
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
NZ199722A (en)	1981-02-25	1985-12-13	Genentech Inc	Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
JPS57149228A (en)	1981-03-11	1982-09-14	Ajinomoto Co Inc	Novel erythropoietin and its preparation
US4873191A (en)	1981-06-12	1989-10-10	Ohio University	Genetic transformation of zygotes
US4792602A (en)	1981-06-19	1988-12-20	Cornell Research Foundation, Inc.	Adaptors, and synthesis and cloning of proinsulin genes
CA1204682A (en)	1981-06-19	1986-05-20	Saran A. Narang	Adaptors, and synthesis and cloning of proinsulin genes
US4714681A (en)	1981-07-01	1987-12-22	The Board Of Reagents, The University Of Texas System Cancer Center	Quadroma cells and trioma cells and methods for the production of same
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
IL66614A (en)	1981-08-28	1985-09-29	Genentech Inc	Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it
AU561343B2 (en)	1981-10-19	1987-05-07	Genentech Inc.	Human immune interferon by recombinant dna
EP0079739A3 (en)	1981-11-12	1984-08-08	The Upjohn Company	Albumin-based nucleotides, their replication and use, and plasmids for use therein
EP0091527A3 (en)	1981-12-14	1984-07-25	The President And Fellows Of Harvard College	Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides
JPS58107298A (en)	1981-12-21	1983-06-25	Yoshitsuka Seiki:Kk	Phase adjusting device for shaker cam in powder molding press
JPS58118008A (en)	1982-01-06	1983-07-13	Nec Corp	Data processor
WO1983002461A1 (en)	1982-01-19	1983-07-21	Cetus Corp	Multiclass hybrid interferons
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
US4450103A (en) *	1982-03-01	1984-05-22	Cetus Corporation	Process for recovering human IFN-β from a transformed microorganism
US4775622A (en)	1982-03-08	1988-10-04	Genentech, Inc.	Expression, processing and secretion of heterologous protein by yeast
US4670393A (en) *	1982-03-22	1987-06-02	Genentech, Inc.	DNA vectors encoding a novel human growth hormone-variant protein
CA1341562C (en)	1982-03-31	2007-11-27	Tadatsugu Taniguchi	Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
EP0091539B2 (en)	1982-03-31	1996-11-27	Ajinomoto Co., Inc.	Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
US5824330A (en)	1982-04-20	1998-10-20	Sloan-Kettering Institute For Cancer Research	Highly purified interleukin-2 and method
US4778879A (en)	1982-04-20	1988-10-18	Sloan-Kettering Institute For Cancer Research	Highly purified human interleukin 2 and method
US4925919A (en) *	1984-04-25	1990-05-15	Roland Mertelsmann	Purified interleukin 2
US4499188A (en) *	1982-05-05	1985-02-12	Cetus Corporation	Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
DE3218121A1 (en)	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Pharmaceutical compositions for tumour treatment
EP0102324A3 (en)	1982-07-29	1984-11-07	Ciba-Geigy Ag	Lipids and surfactants in an aqueous medium
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
US4490289A (en)	1982-09-16	1984-12-25	Hoffmann-La Roche Inc.	Homogeneous human interleukin 2
JPS5945835U (en)	1982-09-16	1984-03-27	株式会社東芝	Arc extinguishing device for circuit breakers and breakers
US4462940A (en) *	1982-09-23	1984-07-31	Cetus Corporation	Process for the recovery of human β-interferon-like polypeptides
US4992271A (en)	1982-09-23	1991-02-12	Cetus Corporation	Formulation for lipophilic IL-2 proteins
FI82266C (en)	1982-10-19	1991-02-11	Cetus Corp	FOERFARANDE FOER FRAMSTAELLNING AV IL-2 MUTEIN.
US4588585A (en)	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) *	1982-11-01	1990-10-30	Cetus Corporation	Expression of interferon genes in Chinese hamster ovary cells
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
EP0116201B1 (en)	1983-01-12	1992-04-22	Chiron Corporation	Secretory expression in eukaryotes
US4840934A (en) *	1983-01-25	1989-06-20	Eleanor Roosevelt Institute For Cancer Research, Inc.	Therapeutic method using T cell growth factor
NZ207394A (en)	1983-03-08	1987-03-06	Commw Serum Lab Commission	Detecting or determining sequence of amino acids
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
DK172738B1 (en)	1983-04-07	1999-06-21	Chiron Corp	Method for expressing mature insulin and DNA structure for use in the method
US5015575A (en) *	1983-04-07	1991-05-14	Chiron Corporation	Hybrid DNA synthesis of insulin
US4914026A (en) *	1983-04-07	1990-04-03	Chiron Corporation	Alpha factor leader sequence directed secretion of insulin
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
JPS60501140A (en)	1983-04-22	1985-07-25	アムジエン	Secretion of exogenous polypeptides by yeast
US5010003A (en) *	1983-04-25	1991-04-23	Genentech, Inc.	Use of yeast homologous signals to secrete heterologous proteins
NZ207926A (en)	1983-04-25	1988-04-29	Genentech Inc	Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
CA1196863A (en) *	1983-06-08	1985-11-19	Mattheus F.A. Goosen	Slow release injectable insulin composition
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4576813A (en)	1983-07-05	1986-03-18	Monsanto Company	Heat recovery from concentrated sulfuric acid
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS6087792A (en)	1983-09-23	1985-05-17	ジェネックス・コーポレイション	Variant control region
EP0142641B1 (en)	1983-09-26	1991-01-16	Udo Dr. Ehrenfeld	Means and product for the diagnosis and therapy of tumours and for the treatment of weaknesses of the cellular and humoral immune system
US4518564A (en) *	1983-10-03	1985-05-21	Jeneric Industries, Inc.	Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations
US4615885A (en)	1983-11-01	1986-10-07	Terumo Kabushiki Kaisha	Pharmaceutical composition containing urokinase
JPS60115528A (en)	1983-11-28	1985-06-22	Takeda Chem Ind Ltd	Human interleukin-2 protein, its production and pharmacological composition containing the same
GB8334102D0 (en)	1983-12-21	1984-02-01	Searle & Co	Interferons with cysteine pattern
US4703008A (en)	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
NZ210501A (en) *	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4855238A (en)	1983-12-16	1989-08-08	Genentech, Inc.	Recombinant gamma interferons having enhanced stability and methods therefor
GB8334261D0 (en)	1983-12-22	1984-02-01	Bass Plc	Fermentation processes
JPS60136596A (en)	1983-12-26	1985-07-20	Suntory Ltd	Peptide and diuretic comprising it as active ingredient
IT1185503B (en)	1984-01-11	1987-11-12	Univ New York	HUMAN Erythropietine ODNA CLONES
US4908433A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Uses of interleukin-2
US4908434A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Process for preparing purified interleukin-2
CA1213537A (en)	1984-05-01	1986-11-04	Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee	Polypeptide expression method
FR2564106B1 (en) *	1984-05-09	1988-04-22	Transgene Sa	FACTOR IX EXPRESSION VECTORS, CELLS TRANSFORMED BY THESE VECTORS, AND PROCESS FOR THE PREPARATION OF FACTOR IX.
DK58285D0 (en)	1984-05-30	1985-02-08	Novo Industri As	PEPTIDES AND MANUFACTURING AND USING THEREOF
EP0172619A1 (en)	1984-06-20	1986-02-26	Takeda Chemical Industries, Ltd.	Novel transformant and use thereof
US4736866B1 (en)	1984-06-22	1988-04-12		Transgenic non-human mammals
US5908763A (en)	1984-07-06	1999-06-01	Novartis Corporation	DNA encoding GM-CSF and a method of producing GM-CSF protein
JPS61227526A (en)	1984-07-25	1986-10-09	Chugai Pharmaceut Co Ltd	Novel csf and method of collecting same
JPS6147500A (en)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	Chimera monoclonal antibody and its preparation
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
US4734491A (en)	1984-08-31	1988-03-29	University Patents, Inc.	DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons
US4716217A (en)	1984-08-31	1987-12-29	University Patents, Inc.	Hybrid lymphoblastoid-leukocyte human interferons
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4959314A (en) *	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
IL77081A (en)	1984-12-04	1999-10-28	Genetics Inst	Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5049386A (en)	1985-01-07	1991-09-17	Syntex (U.S.A.) Inc.	N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en)	1985-01-07	1990-01-30	Syntex (U.S.A.) Inc.	N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en)	1985-01-07	1990-08-07	Syntex (U.S.A.) Inc.	N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4677195A (en)	1985-01-11	1987-06-30	Genetics Institute, Inc.	Method for the purification of erythropoietin and erythropoietin compositions
US4970300A (en) *	1985-02-01	1990-11-13	New York University	Modified factor VIII
GB8504099D0 (en) *	1985-02-18	1985-03-20	Wellcome Found	Physiologically active substances
DK129385A (en)	1985-03-22	1986-09-23	Novo Industri As	PEPTIDES AND PREPARATION THEREOF
FR2579224B1 (en)	1985-03-25	1987-05-22	Genetica	PROCESS FOR THE MICROBIOLOGICAL PREPARATION OF HUMAN SERUM-ALBUMIN
ATE63757T1 (en)	1985-03-28	1991-06-15	Chiron Corp	EXPRESSION THROUGH USE OF FUSION GENES FOR PROTEIN PRODUCTION.
US4751180A (en) *	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
WO1986005807A1 (en)	1985-04-01	1986-10-09	Celltech Limited	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GR860984B (en)	1985-04-17	1986-08-18	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells
GB8510219D0 (en)	1985-04-22	1985-05-30	Bass Plc	Isolation of fermentation products
KR870000428A (en)	1985-06-17	1987-02-18	.	Method of manufacturing human serum albumin
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US5102872A (en) *	1985-09-20	1992-04-07	Cetus Corporation	Controlled-release formulations of interleukin-2
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
JPH0618778B2 (en)	1985-10-04	1994-03-16	中外製薬株式会社	Leukopenia treatment
JPS6296086A (en)	1985-10-21	1987-05-02	Agency Of Ind Science & Technol	Composite plasmid
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US5576195A (en)	1985-11-01	1996-11-19	Xoma Corporation	Vectors with pectate lyase signal sequence
EP0247091B1 (en)	1985-11-01	1993-09-29	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
CA1295563C (en)	1985-11-01	1992-02-11	Robert T. Garvin	Production of active proteins containing cystine residues
US5641663A (en) *	1985-11-06	1997-06-24	Cangene Corporation	Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
CA1295566C (en)	1987-07-21	1992-02-11	Robert T. Garvin	Characterization and structure of genes for protease a and protease b from streptomyces griseus
JPH0780930B2 (en)	1985-12-26	1995-08-30	三井石油化学工業株式会社	Method for polymerizing α-olefin
JPH0645551B2 (en)	1986-01-07	1994-06-15	塩野義製薬株式会社	Interleukin-2 composition
CA1297005C (en)	1986-01-22	1992-03-10	Masahiko Tamura	Pharmaceutical agent for the treatment of myelogenous leukemia
ES2039209T5 (en)	1986-01-22	1996-07-16	Chugai Pharmaceutical Co Ltd	PHARMACEUTICAL COMPOUND THAT PROMOTES THE RESTORATION OF HEMOPOYETIC CAPACITY.
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
FR2594846B1 (en)	1986-02-21	1989-10-20	Genetica	PROCESS FOR THE PREPARATION OF MATURE HUMAN ALBUMIN SERUM
EP0237019A3 (en)	1986-03-14	1988-03-09	Toray Industries, Inc.	Interferon conjugate and production thereof using recombinant gene
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
IT1203758B (en)	1986-03-27	1989-02-23	Univ Roma	CLONING AND EXPRESSION VECTORS OF HETEROLOGICAL GENES IN YEASTS AND YEASES TRANSFORMED WITH SUCH CARRIERS
DK179286D0 (en)	1986-04-18	1986-04-18	Nordisk Gentofte	INSULIN PREPARATION
US4765980A (en)	1986-04-28	1988-08-23	International Minerals & Chemical Corp.	Stabilized porcine growth hormone
US4859609A (en)	1986-04-30	1989-08-22	Genentech, Inc.	Novel receptors for efficient determination of ligands and their antagonists or agonists
US5028422A (en) *	1986-05-27	1991-07-02	Schering Corporation	Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5985599A (en)	1986-05-29	1999-11-16	The Austin Research Institute	FC receptor for immunoglobulin
IT1204400B (en) *	1986-06-20	1989-03-01	Sclavo Spa	PHARMACEUTICAL COMPOSITIONS CONTAINING A CALCITONIN
GB8615701D0 (en)	1986-06-27	1986-08-06	Delta Biotechnology Ltd	Stable gene integration vector
IT1196484B (en)	1986-07-11	1988-11-16	Sclavo Spa	YEAST EXPRESSION AND SECRETION VECTOR, USEFUL FOR THE PREPARATION OF HETEROLOGICAL PROTEINS
GR871067B (en)	1986-07-18	1987-11-19	Chugai Pharmaceutical Co Ltd	Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US4857467A (en)	1986-07-23	1989-08-15	Phillips Petroleum Company	Carbon and energy source markers for transformation of strains of the genes Pichia
US4801575A (en) *	1986-07-30	1989-01-31	The Regents Of The University Of California	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5002764A (en) *	1986-08-12	1991-03-26	Schering Corporation	Treatment of actinic keratoses with alpha2 interferon
GB8620926D0 (en) *	1986-08-29	1986-10-08	Delta Biotechnology Ltd	Yeast promoter
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4929442A (en) *	1986-09-26	1990-05-29	Exovir, Inc.	Compositions suitable for human topical application including a growth factor and/or related materials
US5508031A (en) *	1986-11-21	1996-04-16	Cetus Oncology Corporation	Method for treating biological damage using a free-radial scavenger and interleukin-2
WO1988007057A1 (en)	1987-03-13	1988-09-22	Amgen Inc.	Purified platelet-derived growth factor and methods for purification thereof
US4835260A (en) *	1987-03-20	1989-05-30	Genetics Institute, Inc.	Erythropoietin composition
AU613030B2 (en) *	1987-04-09	1991-07-25	Novozymes Delta Limited	Yeast vector
ATE142264T1 (en)	1987-04-22	1996-09-15	Chiron Corp	RECOMBINANT PRODUCTION OF A-CHAIN POLYPEPTIDES OF PDGF
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5489425A (en)	1987-06-24	1996-02-06	The Dow Chemical Company	Functionalized polyamine chelants
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
IL87258A (en)	1987-07-28	1994-02-27	Gist Brocades Nv	Kluyveromyces host cells and their use for expressing polypeptides
JPH0622784Y2 (en)	1987-08-04	1994-06-15	東洋シヤッター株式会社	Height adjustment device for movable center pillar for over door
JP2627899B2 (en)	1987-08-19	1997-07-09	株式会社ビタミン研究所	Production method of gene-encapsulated liposome
SE459586B (en)	1987-09-14	1989-07-17	Mta Szegedi Biolog Koezponti	THE STRUCTURES CODING FOR AUTHENTIC HUMAN SERUM ALBUMIN AND PROCEDURES FOR ITS PREPARATION
US5336603A (en) *	1987-10-02	1994-08-09	Genentech, Inc.	CD4 adheson variants
PT88641B (en)	1987-10-02	1993-04-30	Genentech Inc	METHOD FOR PREPARING A VARIETY OF ADHESION
JPH0811074B2 (en)	1987-10-30	1996-02-07	財団法人化学及血清療法研究所	Recombinant plasmid incorporating a gene encoding prealbumin and method for producing prealbumin using the same
GB8725529D0 (en)	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
GB8726953D0 (en)	1987-11-18	1987-12-23	Delta Biotechnology Ltd	Yeast expression system
JP2791418B2 (en) *	1987-12-02	1998-08-27	株式会社ミドリ十字	Method for producing heterologous protein, recombinant DNA, transformant
US5282856A (en)	1987-12-22	1994-02-01	Ledergerber Walter J	Implantable prosthetic device
ZA89430B (en)	1988-01-22	1989-10-25	Gen Hospital Corp	Cloned genes encoding ig-cd4 fusion proteins and the use thereof
JPH01240191A (en) *	1988-02-16	1989-09-25	Green Cross Corp:The	Novel signal peptide functioning by yeast and secretory manifestation of foreign protein using same
JPH01215289A (en)	1988-02-22	1989-08-29	Toa Nenryo Kogyo Kk	Production of normal human serum albumin a through gene recombination
US4999339A (en) *	1988-03-28	1991-03-12	Cetus Corporation	Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5066489A (en)	1988-03-28	1991-11-19	Cetus Corporation	Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5061488A (en)	1988-04-15	1991-10-29	The United States Of America As Represented Department Of Health & Human Services	Flavone-8-acetic acid and interleukin-2 for cancer therapy
US5763394A (en) *	1988-04-15	1998-06-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5981485A (en)	1997-07-14	1999-11-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5096707A (en) *	1988-04-15	1992-03-17	The United States Of America As Represented By The Department Of Health And Human Services	Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
US5096885A (en) *	1988-04-15	1992-03-17	Genentech, Inc.	Human growth hormone formulation
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
IL89992A0 (en)	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human serum albumin in methylotrophic yeasts
IL89989A0 (en)	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human interleukin-2 in methylotrophic yeasts
US5126129A (en) *	1988-05-23	1992-06-30	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services	Cancer therapy using interleukin-2 and flavone compounds
ATE101620T1 (en)	1988-06-23	1994-03-15	Hoechst Ag	MINI-PROINSULIN, ITS PREPARATION AND USE.
CA1341373C (en)	1988-06-24	2002-07-02	Roberta C. Cheng	Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5756065A (en)	1988-06-24	1998-05-26	The Dow Chemical Company	Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
CN1033030C (en)	1988-06-24	1996-10-16	唐化学原料公司	Preparation method of macrocyclic bifunctional chelating agent and its complexes and antibody conjugates
US5274119A (en)	1988-07-01	1993-12-28	The Dow Chemical Company	Vicinal diols
JP3092811B2 (en)	1988-07-23	2000-09-25	デルタバイオテクノロジーリミテッド	Peptide and DNA sequences
US4925648A (en)	1988-07-29	1990-05-15	Immunomedics, Inc.	Detection and treatment of infectious and inflammatory lesions
FR2649991B2 (en)	1988-08-05	1994-03-04	Rhone Poulenc Sante	USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES
FR2635115B1 (en)	1988-08-05	1992-04-03	Rhone Poulenc Sante	PROCESS FOR THE PREPARATION OF HUMAN ALBUMIN SERUM FROM YEAST
US5601819A (en)	1988-08-11	1997-02-11	The General Hospital Corporation	Bispecific antibodies for selective immune regulation and for selective immune cell binding
AU4216689A (en)	1988-08-11	1990-03-05	California Biotechnology, Inc.	Method for stabilizing heterologous protein expression and vectors for use therein
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
DE68927933T2 (en)	1988-09-02	1997-08-14	Dyax Corp	PRODUCTION AND SELECTION OF RECOMBINANT PROTEINS WITH DIFFERENT BINDING POINTS
US5260202A (en)	1988-09-07	1993-11-09	Delta Biotechnology Limited	Fermentation method
JPH02227079A (en)	1988-10-06	1990-09-10	Tonen Corp	human serum albumin fragment
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5298243A (en)	1988-10-20	1994-03-29	Denki Kagaku Kogyo Kabushiki Kaisha	Colony stimulating factor-gelatin conjugate
JPH02117384A (en)	1988-10-26	1990-05-01	Tonen Corp	Production of human serum albumin A by yeast hosts
US5759802A (en)	1988-10-26	1998-06-02	Tonen Corporation	Production of human serum alubumin A
WO1990004788A1 (en)	1988-10-28	1990-05-03	Genentech, Inc.	Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5342604A (en)	1988-10-31	1994-08-30	The Dow Chemical Company	Complexes possessing ortho ligating functionality
US5696239A (en)	1988-10-31	1997-12-09	The Dow Chemical Company	Conjugates possessing ortho ligating functionality and complexes thereof
US5256410A (en)	1988-12-01	1993-10-26	Schering Corporation	Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US4975271A (en)	1988-12-19	1990-12-04	Vipont Pharmaceutical, Inc.	Muscosal delivery systems for treatment of periodontal disease
EP0401384B1 (en)	1988-12-22	1996-03-13	Kirin-Amgen, Inc.	Chemically modified granulocyte colony stimulating factor
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
DK105489D0 (en) *	1989-03-03	1989-03-03	Novo Nordisk As	POLYPEPTIDE
US5096815A (en)	1989-01-06	1992-03-17	Protein Engineering Corporation	Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en)	1989-01-06	1993-03-30	Protein Engineering Corp.	Generation and selection of novel DNA-binding proteins and polypeptides
US5116964A (en) *	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5705363A (en)	1989-03-02	1998-01-06	The Women's Research Institute	Recombinant production of human interferon τ polypeptides and nucleic acids
JPH04504246A (en)	1989-03-20	1992-07-30	ザ・ジェネラル・ホスピタル・コーポレーション	insulin stimulating hormone
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5693622A (en)	1989-03-21	1997-12-02	Vical Incorporated	Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
WO1990011092A1 (en)	1989-03-21	1990-10-04	Vical, Inc.	Expression of exogenous polynucleotide sequences in a vertebrate
US5231020A (en)	1989-03-30	1993-07-27	Dna Plant Technology Corporation	Genetic engineering of novel plant phenotypes
US5328470A (en)	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
ATE79763T1 (en) *	1989-04-11	1992-09-15	Boehringer Ingelheim Int	USE OF AT LEAST ONE CYTOKINE IN THE MANUFACTURE OF A MEDICATION FOR THE SYSTEMIC TREATMENT OF PRAENEOPLASTIC LESIONS.
FI901810A7 (en)	1989-04-13	1990-10-14	Vascular Laboratory Inc	Plasminogen activator complex of pure pro-urokinase bound to human serum albumin via a disulfide bridge
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
EP0394827A1 (en)	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Chimaeric CD4-immunoglobulin polypeptides
ATE92107T1 (en)	1989-04-29	1993-08-15	Delta Biotechnology Ltd	N-TERMINAL FRAGMENTS OF HUMAN SERUM ALBUMIN-CONTAINING FUSION PROTEINS.
GB8909916D0 (en)	1989-04-29	1989-06-14	Delta Biotechnology Ltd	Polypeptides
US5766883A (en) *	1989-04-29	1998-06-16	Delta Biotechnology Limited	Polypeptides
US5332671A (en)	1989-05-12	1994-07-26	Genetech, Inc.	Production of vascular endothelial cell growth factor and DNA encoding same
ATE155813T1 (en)	1989-05-19	1997-08-15	Genentech Inc	HER2 EXTRACELLULAR DOMAIN
CA2017379C (en)	1989-05-24	2002-06-25	Kenneth A. Thomas, Jr.	Purification and characterization of a glioma-derived growth factor
US5808003A (en)	1989-05-26	1998-09-15	Perimmune Holdings, Inc.	Polyaminocarboxylate chelators
WO1990015142A1 (en)	1989-06-09	1990-12-13	Gropep Pty. Ltd.	Growth hormone fusion proteins
JPH0327320A (en)	1989-06-26	1991-02-05	Ajinomoto Co Inc	Human b cell differentiation factor pharmaceutical composition
EP0739904A1 (en)	1989-06-29	1996-10-30	Medarex, Inc.	Bispecific reagents for aids therapy
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
DE3924746A1 (en) *	1989-07-26	1991-01-31	Behringwerke Ag	ERTHROPOIETIN (EPO) PEPTIDES AND ANTIBODIES THEREFOR
FR2650598B1 (en) *	1989-08-03	1994-06-03	Rhone Poulenc Sante	DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
CU22222A1 (en)	1989-08-03	1995-01-31	Cigb	PROCEDURE FOR THE EXPRESSION OF HETEROLOGICAL PROTEINS PRODUCED IN A FUSION FORM IN ESCHERICHIA COLI, ITS USE, EXPRESSION VECTORS AND RECOMBINANT STRAINS
GB8927480D0 (en)	1989-12-05	1990-02-07	Delta Biotechnology Ltd	Mutant fungal strain detection and new promoter
US5073627A (en) *	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3
DK0489116T3 (en)	1989-08-22	1994-05-02	Immunex Corp	Fusion proteins comprising GM-CSF and IL-3
US5436146A (en)	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
US6063373A (en) *	1989-09-19	2000-05-16	Maxim Pharmaceuticals, Inc.	Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
CA1340994C (en)	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Treatment of conditions and disease
IE66494B1 (en)	1989-09-26	1996-01-10	Immunex Corp	Granulocyte-colony stimulating factor receptors
WO1991005052A1 (en)	1989-09-28	1991-04-18	Leningradsky Gosudarstvenny Universitet	Method for obtaining a polypeptide with human-interleukin-2 activity, secreted by yeast cells, saccharomyces cerevisiae
WO1991005058A1 (en)	1989-10-05	1991-04-18	Glenn Kawasaki	Cell-free synthesis and isolation of novel genes and polypeptides
FR2653020B1 (en)	1989-10-17	1993-03-26	Roussel Uclaf	USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEUKEMIA.
US5667986A (en)	1989-10-18	1997-09-16	Delta Biotechnology Limited	Yeast promoter for expressing heterologous polypeptides
GB8924021D0 (en)	1989-10-25	1989-12-13	Celltech Ltd	Recombinant dna method and vectors for the use therein
US5676954A (en)	1989-11-03	1997-10-14	Vanderbilt University	Method of in vivo delivery of functioning foreign genes
EP0452457B1 (en)	1989-11-03	1997-08-20	Vanderbilt University	Method of in vivo delivery of functioning foreign genes
US5580560A (en) *	1989-11-13	1996-12-03	Novo Nordisk A/S	Modified factor VII/VIIa
US5173408A (en)	1989-11-13	1992-12-22	Lange Louis George Iii	Mammalian pancreatic cholesterol esterase
DK608589D0 (en)	1989-12-01	1989-12-01	Holm Arne	CHEMICAL PROCEDURE
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5116944A (en) *	1989-12-29	1992-05-26	Neorx Corporation	Conjugates having improved characteristics for in vivo administration
JPH03201987A (en)	1989-12-29	1991-09-03	Tonen Corp	human serum albumin fragment
AU7247191A (en)	1990-01-11	1991-08-05	Molecular Affinities Corporation	Production of antibodies using gene libraries
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
ES2284161T3 (en)	1990-01-12	2007-11-01	Amgen Fremont Inc.	GENERATION OF XENOGENIC ANTIBODIES.
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
ES2113879T3 (en)	1990-01-24	1998-05-16	Douglas I Buckley	GLP-1 ANALOGS USEFUL FOR THE TREATMENT OF DIABETES.
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
ES2086521T3 (en) *	1990-01-25	1996-07-01	Univ Washington	LACI-FACTOR X HYBRID PROTEIN.
JPH04211375A (en)	1990-02-05	1992-08-03	Ajinomoto Co Inc	Synthetic gene and production of human serum albumin using the synthetic gene
US5747334A (en)	1990-02-15	1998-05-05	The University Of North Carolina At Chapel Hill	Random peptide library
US5208018A (en) *	1990-03-19	1993-05-04	Brigham And Women's Hospital	Treatment of cachexia with interleukin 2
FR2660863B1 (en) *	1990-04-17	1994-01-21	Roussel Uclaf	USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PRIMITIVE CANCERS OF THE POWDER.
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
WO1991018088A1 (en)	1990-05-23	1991-11-28	The United States Of America, Represented By The Secretary, United States Department Of Commerce	Adeno-associated virus (aav)-based eucaryotic vectors
GB9013017D0 (en)	1990-06-11	1990-08-01	Mars Uk Ltd	Compounds
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
ES2063515T3 (en)	1990-07-10	1995-01-01	Boehringer Ingelheim Int	IFN-ALPHA O-GLYCOSYLATED.
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5225341A (en)	1990-07-19	1993-07-06	The Regents Of The University Of California	Biologically safe plant transformation system using a ds transposon
US5202239A (en) *	1990-08-07	1993-04-13	Scios Nova Inc.	Expression of recombinant polypeptides with improved purification
US5071872A (en)	1990-08-14	1991-12-10	The Ohio State University Research Foundation	Method for improving interleukin-2 activity using aci-reductone compounds
DE69133476T2 (en)	1990-08-29	2006-01-05	GenPharm International, Inc., Palo Alto	Transgenic mice capable of producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5391183A (en) *	1990-09-21	1995-02-21	Datascope Investment Corp	Device and method sealing puncture wounds
IT1242149B (en)	1990-09-27	1994-02-16	Consiglio Nazionale Ricerche	CODING NUCLEOTID SEQUENCE FOR A HUMAN PROTEIN WITH REGULATORY PROPERTIES OF ANGIOGENESIS
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
JP3583420B2 (en)	1990-10-05	2004-11-04	メダレツクス・インコーポレーテツド	Targeted immunization with bispecific reagents
JPH07108232B2 (en)	1990-10-09	1995-11-22	エム・ディ・リサーチ株式会社	Method for producing peptide or protein
JPH0638771Y2 (en)	1990-10-26	1994-10-12	株式会社カンセイ	Airbag control device
EP0557300B1 (en)	1990-10-29	1997-11-19	Chiron Corporation	Bispecific antibodies, method of production, and uses thereof
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
FR2668368B1 (en)	1990-10-30	1995-03-10	Roussel Uclaf	USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MALIGNANT EPITHELIAL TUMORS.
JPH0638771A (en)	1990-10-31	1994-02-15	Tonen Corp	Method for expressing human protein disulfide isomerase gene and method for producing polypeptide by co-expression with the gene
US5353535A (en)	1990-11-05	1994-10-11	Plumly George W	Floor type advertising apparatus
US5830452A (en)	1990-11-20	1998-11-03	Chiron Corporation	Method for enhancing the anti-tumor therapeutic index of interleukin-2
AU656353B2 (en)	1990-11-29	1995-02-02	Institut National De La Recherche Agronomique (Inra)	New variants derived from interferons of type I, production process thereof and their applications
CA2405246A1 (en)	1990-12-03	1992-06-11	Genentech, Inc.	Enrichment method for variant proteins with alterred binding properties
US5272080A (en) *	1991-02-19	1993-12-21	Pharmavene, Inc.	Production of butyrylcholinesterase
WO1994027631A1 (en) *	1993-05-21	1994-12-08	Zymogenetics, Inc.	Modified factor vii
US5833982A (en)	1991-02-28	1998-11-10	Zymogenetics, Inc.	Modified factor VII
US5272070A (en) *	1991-03-08	1993-12-21	Board Of Regents, The University Of Texas System	Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
CA2062659A1 (en)	1991-03-12	1992-09-13	Yasutaka Igari	Composition for sustained-release of erythropoietin
US5811396A (en)	1991-03-14	1998-09-22	The United States Of America As Represented By The Department Of Health And Human Services	TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor
EP0506477B1 (en)	1991-03-28	1999-06-23	Merck & Co. Inc.	Vascular endothelial cell growth factor C subunit
US5374617A (en)	1992-05-13	1994-12-20	Oklahoma Medical Research Foundation	Treatment of bleeding with modified tissue factor in combination with FVIIa
CA2108147C (en)	1991-04-10	2009-01-06	Angray Kang	Heterodimeric receptor libraries using phagemids
EP0509841A3 (en)	1991-04-18	1993-08-18	Tonen Corporation	Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system
CA2058820C (en)	1991-04-25	2003-07-15	Kotikanyad Sreekrishna	Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
JP3431140B2 (en)	1991-04-26	2003-07-28	サーフィス・アクティブ・リミテッド	Antibodies and methods of use
US5330901A (en)	1991-04-26	1994-07-19	Research Corporation Technologies, Inc.	Expression of human serum albumin in Pichia pastoris
FR2676070B1 (en)	1991-04-30	1994-09-30	Rhone Poulenc Rorer Sa	YEAST PROMOTER AND ITS USE.
US5646012A (en) *	1991-04-30	1997-07-08	Rhone-Poulenc Rorer S.A.	Yeast promoter and use thereof
DE69233482T2 (en)	1991-05-17	2006-01-12	Merck & Co., Inc.	Method for reducing the immunogenicity of antibody variable domains
IL101943A0 (en)	1991-05-24	1992-12-30	Genentech Inc	Structure,production and use of heregulin
US5304473A (en) *	1991-06-11	1994-04-19	Eli Lilly And Company	A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
EP0590067A1 (en)	1991-06-14	1994-04-06	Xoma Corporation	Microbially-produced antibody fragments and their conjugates
FR2677996B1 (en)	1991-06-21	1993-08-27	Rhone Poulenc Rorer Sa	CLONING AND / OR EXPRESSION VECTORS PREPARATION AND USE.
US5844095A (en) *	1991-06-27	1998-12-01	Bristol-Myers Squibb Company	CTLA4 Ig fusion proteins
US5851795A (en)	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
AU2147192A (en)	1991-06-28	1993-01-25	Genentech Inc.	Method of stimulating immune response using growth hormone
US5223408A (en)	1991-07-11	1993-06-29	Genentech, Inc.	Method for making variant secreted proteins with altered properties
JPH05292972A (en)	1991-07-29	1993-11-09	Tonen Corp	Improved yeast expression system
WO1993003164A1 (en)	1991-07-31	1993-02-18	Rhone-Poulenc Rorer International (Holdings) Inc.	Transgenic protein production
US5723719A (en)	1991-08-08	1998-03-03	Health Research Inc.	Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (en)	1991-08-14	1993-02-18	Detlev Prof Dr Med Ganten	Transgenic rats that contain at least one human gene in their genome that is involved in blood pressure regulation
ES2136092T3 (en)	1991-09-23	1999-11-16	Medical Res Council	PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
NZ245015A (en) *	1991-11-05	1995-12-21	Transkaryotic Therapies Inc	Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US6270989B1 (en)	1991-11-05	2001-08-07	Transkaryotic Therapies, Inc.	Protein production and delivery
CA2122717C (en) *	1991-11-08	2003-07-15	David C. Anderson	Hemoglobins as drug delivery agents
US5786883A (en) *	1991-11-12	1998-07-28	Pilkington Barnes Hind, Inc.	Annular mask contact lenses
ES2341666T3 (en)	1991-12-02	2010-06-24	Medimmune Limited	PRODUCTION OF AUTHORTIC BODIES OF REPERTORIES OF ANTIQUE RPOS SEGMENTS EXPRESSED ON THE FAGOS SURFACE.
US5540923A (en) *	1991-12-06	1996-07-30	Landsforeningen Til Kraeftens Bekaemplse	Interferon proteins
US6348327B1 (en) *	1991-12-06	2002-02-19	Genentech, Inc.	Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
US5428139A (en)	1991-12-10	1995-06-27	The Dow Chemical Company	Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
DK0620849T3 (en)	1992-01-07	2003-10-20	Elan Pharm Inc	Transgenic animal models for Alzheimer's disease
GB9200417D0 (en)	1992-01-09	1992-02-26	Bagshawe Kenneth D	Cytotoxic drug therapy
FR2686620B1 (en) *	1992-01-27	1995-06-23	Rhone Poulenc Rorer Sa	HUMAN SERUM-ALBUMIN, PREPARATION AND USE.
FR2686899B1 (en) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686900B1 (en)	1992-01-31	1995-07-21	Rhone Poulenc Rorer Sa	NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686901A1 (en)	1992-01-31	1993-08-06	Rhone Poulenc Rorer Sa	NOVEL ANTITHROMBOTIC POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ATE295420T1 (en)	1992-02-06	2005-05-15	Chiron Corp	MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT
ES2193143T3 (en)	1992-03-05	2003-11-01	Univ Texas	USE OF IMMUNOCONJUGADOS FOR THE DIAGNOSIS AND / OR THERAPY OF VASCULARIZA TUMORS.
US5230886A (en)	1992-03-18	1993-07-27	Trustees Of Boston University	Tumor cell suppression
DK36392D0 (en) *	1992-03-19	1992-03-19	Novo Nordisk As	USE OF CHEMICAL COMPOUND
USRE37302E1 (en)	1992-03-19	2001-07-31	Novo Nordisk A/S	Peptide
DK36492D0 (en)	1992-03-19	1992-03-19	Novo Nordisk As	PREPARATION
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
US5460954A (en)	1992-04-01	1995-10-24	Cheil Foods & Chemicals, Inc.	Production of human proinsulin using a novel vector system
US5229109A (en)	1992-04-14	1993-07-20	Board Of Regents, The University Of Texas System	Low toxicity interleukin-2 analogues for use in immunotherapy
KR970000862B1 (en)	1992-06-09	1997-01-20	호프 아크티엔게젤샤프트	Latch and Lock
KR0154880B1 (en)	1992-06-15	1998-10-15	피터 알.셰어러	Glucagon-like peptides and insulinotropin derivatives
US5686268A (en) *	1992-06-19	1997-11-11	Pfizer Inc.	Fused proteins
US5505931A (en)	1993-03-04	1996-04-09	The Dow Chemical Company	Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
JP3269504B2 (en)	1992-07-08	2002-03-25	三菱ウェルファーマ株式会社	Method for producing human serum albumin
FR2694294B1 (en) *	1992-07-30	1994-09-09	Rhone Poulenc Rorer Sa	Yeast promoter and its user.
DE69334134T2 (en)	1992-07-31	2007-12-20	Genentech, Inc., South San Francisco	Aqueous formulation containing human growth hormone
US5602307A (en)	1992-08-12	1997-02-11	Baylor College Of Medicine	Non-human animal having predefined allele of a cellular adhesion gene
DE4244915C2 (en)	1992-08-14	1998-12-03	Widmar Prof Dr Tanner	Fungal cells contg. mutated DPM2 mannosyl transferase gene
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5728553A (en) *	1992-09-23	1998-03-17	Delta Biotechnology Limited	High purity albumin and method of producing
US5731490A (en)	1992-09-29	1998-03-24	The Ontario Cancer Institute	Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
AU5171293A (en) *	1992-10-14	1994-05-09	Regents Of The University Of Colorado, The	Ion-pairing of drugs for improved efficacy and delivery
FR2697752B1 (en) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Antitumor compositions containing taxane derivatives.
TW402639B (en)	1992-12-03	2000-08-21	Transkaryotic Therapies Inc	Protein production and protein delivery
US5478745A (en)	1992-12-04	1995-12-26	University Of Pittsburgh	Recombinant viral vector system
US5441050A (en)	1992-12-18	1995-08-15	Neoprobe Corporation	Radiation responsive surgical instrument
US6221958B1 (en) *	1993-01-06	2001-04-24	Societe De Conseils De Recherches Et D'applications Scientifiques, Sas	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5489743A (en)	1993-01-19	1996-02-06	Amgen Inc.	Transgenic animal models for thrombocytopenia
US5593972A (en)	1993-01-26	1997-01-14	The Wistar Institute	Genetic immunization
FR2701953B1 (en)	1993-02-22	1995-05-24	Centre Nat Rech Scient	Multi-VIP fusion protein and method for preparing recombinant VIP.
US5441734A (en) *	1993-02-25	1995-08-15	Schering Corporation	Metal-interferon-alpha crystals
US5780021A (en)	1993-03-05	1998-07-14	Georgetown University	Method for treating type 1 diabetes using α-interferon and/or β-i
US5869445A (en)	1993-03-17	1999-02-09	University Of Washington	Methods for eliciting or enhancing reactivity to HER-2/neu protein
US6284727B1 (en)	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
HU225496B1 (en)	1993-04-07	2007-01-29	Scios Inc	Pharmaceutical compositions of prolonged delivery, containing peptides
AU6709794A (en)	1993-04-21	1994-11-08	Brigham And Women's Hospital	Erythropoietin muteins with enhanced activity
GB9308581D0 (en)	1993-04-26	1993-06-09	Univ Manitoba	A method for induction of antigen-specific suppression of immune-response
ATE301201T1 (en)	1993-06-07	2005-08-15	Vical Inc	PLASMIDS USABLE FOR GENE THERAPY
US5621039A (en) *	1993-06-08	1997-04-15	Hallahan; Terrence W.	Factor IX- polymeric conjugates
DK82893D0 (en) *	1993-07-08	1993-07-08	Novo Nordisk As	PEPTIDE
US5512459A (en)	1993-07-20	1996-04-30	Bionebraska, Inc.	Enzymatic method for modification or recombinant polypeptides
AU693459B2 (en)	1993-08-09	1998-07-02	Edward Baral	A method for sensitization of cancer cells for killer cell mediated lysis
ZA946122B (en)	1993-08-17	1995-03-20	Amgen Inc	Erythropoietin analogs
WO1995005848A1 (en)	1993-08-24	1995-03-02	Novo Nordisk A/S	Protracted glp-1
GB9317618D0 (en)	1993-08-24	1993-10-06	Royal Free Hosp School Med	Polymer modifications
US5521086A (en) *	1993-09-16	1996-05-28	Cephalon, Inc.	Secretion sequence for the production of a heterologous protein in yeast
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5459031A (en)	1993-11-05	1995-10-17	Amgen Inc.	Methods for controlling sialic acid derivatives in recombinant glycoproteins
WO1995015982A2 (en)	1993-12-08	1995-06-15	Genzyme Corporation	Process for generating specific antibodies
CA2137206A1 (en)	1993-12-09	1995-06-10	John A. Galloway	Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
AU1272295A (en)	1993-12-17	1995-07-03	Novo Nordisk A/S	Proinsulin-like compounds
DK144093D0 (en)	1993-12-23	1993-12-23	Novo Nordisk As
EP0744958B1 (en)	1994-01-31	2003-06-25	Trustees Of Boston University	Polyclonal antibody libraries
US5550214A (en)	1994-02-10	1996-08-27	Brigham And Women's Hospital	Isolated antigenic oncogene peptide fragments and uses
US5834252A (en)	1995-04-18	1998-11-10	Glaxo Group Limited	End-complementary polymerase reaction
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US5932780A (en)	1994-02-28	1999-08-03	Yissum Research Development Company Of Hebrew University Of Jerusalem	Transgenic non-human animal assay system for anti-cholinesterase substances
GB9404270D0 (en)	1994-03-05	1994-04-20	Delta Biotechnology Ltd	Yeast strains and modified albumins
US6608182B1 (en)	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
US5629286A (en) *	1994-03-31	1997-05-13	Brewitt; Barbara	Homeopathic dilutions of growth factors
US5652352A (en)	1994-03-31	1997-07-29	Amgen Inc.	Afamin: a human serum albumin-like gene
US5646113A (en)	1994-04-07	1997-07-08	Genentech, Inc.	Treatment of partial growth hormone insensitivity syndrome
FR2719593B1 (en)	1994-05-06	1996-05-31	Rhone Poulenc Rorer Sa	New biologically active polypeptides, their preparation and pharmaceutical composition containing them.
GB9409496D0 (en)	1994-05-12	1994-06-29	London Health Ass	Method for improving glycaemic control in diabetes
GB9411356D0 (en)	1994-06-07	1994-07-27	Delta Biotechnology Ltd	Yeast strains
US5516637A (en)	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en)	1994-06-15	1999-11-16	Systemix, Inc.	Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639642A (en)	1994-06-16	1997-06-17	Novo Nordisk A/S	Synthetic leader peptide sequences
US5623054A (en)	1994-06-23	1997-04-22	The General Hospital Corporation	Crucifer AFT proteins and uses thereof
JPH10506004A (en)	1994-07-27	1998-06-16	ザカウンシルオブザクィーンズランドインスティテュートオブメディカルリサーチ	Polyepitope vaccine
JPH0853500A (en)	1994-08-11	1996-02-27	Asahi Glass Co Ltd	Fusion protein and gene encoding the protein
JPH0851982A (en)	1994-08-11	1996-02-27	Asahi Glass Co Ltd	Modified gene encoding human serum albumin
JPH0859509A (en)	1994-08-16	1996-03-05	Teijin Ltd	Agent for treating cytomegalovirus antigenemia and agent for treating cytomegalovirus infectious disease
US5574008A (en)	1994-08-30	1996-11-12	Eli Lilly And Company	Biologically active fragments of glucagon-like insulinotropic peptide
US6071923A (en) *	1994-09-16	2000-06-06	Bar-Ilan University	Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
FR2726576B1 (en)	1994-11-07	1997-01-31	Pf Medicament	PRODUCTION OF HYDROPHOBIC PEPTIDE-LIKE PEPTIDES, RECOMBINANT PEPTIDE, CORRESPONDING DNA SEQUENCE
FR2726471B1 (en)	1994-11-07	1997-01-31	Pf Medicament	PROCESS FOR IMPROVING THE IMMUNOGENICITY OF AN IMMUNOGENIC COMPOUND OR A HAPTENA AND APPLICATION TO THE PREPARATION OF VACCINES
CA2203655C (en)	1994-11-07	2010-03-23	Guo-Liang Yu	Tumor necrosis factor-gamma
AT403167B (en)	1994-11-14	1997-11-25	Immuno Ag	SELECTION AND EXPRESSION OF FOREIGN PROTEINS BY MEANS OF A SELECTION-AMPLIFICATION SYSTEM
US5695750A (en)	1994-11-25	1997-12-09	The United States Of America As Represented By The Secretary Of The Army	Compositions for use to deactivate organophosphates
EP0796335A1 (en)	1994-12-07	1997-09-24	Bionebraska, Inc.	Production of peptides using recombinant fusion protein constructs
WO1996017941A2 (en)	1994-12-07	1996-06-13	Bionebraska, Inc.	Production of c-terminal amidated peptides from recombinant protein constructs
CA2205572A1 (en)	1994-12-12	1996-06-20	Beth Israel Hospital Association	Chimeric cytokines and uses thereof
US20010006943A1 (en)	1994-12-23	2001-07-05	Ejvind Jensen	Protracted GLP-1 compositions
EP0796106B1 (en)	1994-12-23	2003-03-19	Novo Nordisk A/S	Protracted glp-1 compositions
US5583415A (en)	1994-12-27	1996-12-10	Motorola, Inc.	Apparatus for simulating high battery temperature for rechargeble battery systems
US5652224A (en)	1995-02-24	1997-07-29	The Trustees Of The University Of Pennsylvania	Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5928939A (en)	1995-03-01	1999-07-27	Ludwig Institute For Cancer Research	Vascular endothelial growth factor-b and dna coding therefor
US5837281A (en) *	1995-03-17	1998-11-17	Takeda Chemical Industries, Ltd.	Stabilized interface for iontophoresis
JP2758154B2 (en)	1995-04-06	1998-05-28	エフ・ホフマン−ラロシユアーゲー	Liquid preparations containing interferon
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
EP0822984A4 (en)	1995-04-27	2000-05-03	Human Genome Sciences Inc	Human tumor necrosis factor receptors
ATE390933T1 (en)	1995-04-27	2008-04-15	Amgen Fremont Inc	HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	Human antibodies derived from immunized xenomice
US5480640A (en)	1995-05-02	1996-01-02	Schering Corporation	Alpha interferon for treating prostate cancer
CN1125082C (en)	1995-05-05	2003-10-22	人类基因组科学公司	Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4
AU5724996A (en)	1995-05-05	1996-11-21	Eli Lilly And Company	Single chain insulin with high bioactivity
US5728915A (en)	1995-05-08	1998-03-17	Children's Hospital, Inc.	Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5705151A (en)	1995-05-18	1998-01-06	National Jewish Center For Immunology & Respiratory Medicine	Gene therapy for T cell regulation
US6001625A (en)	1995-05-19	1999-12-14	The United States Of America As Represented By The Secretary Of The Army	Site-directed mutagenesis of esterases
US6387365B1 (en)	1995-05-19	2002-05-14	Schering Corporation	Combination therapy for chronic hepatitis C infection
US5741815A (en) *	1995-06-02	1998-04-21	Lai; Ching-San	Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5804162A (en)	1995-06-07	1998-09-08	Alliance Pharmaceutical Corp.	Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5728707A (en) *	1995-07-21	1998-03-17	Constantia Gruppe	Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US5811097A (en)	1995-07-25	1998-09-22	The Regents Of The University Of California	Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5840542A (en)	1995-07-28	1998-11-24	Mogam Biotechnology Research Institute	Method for manufacture of proinsulin with high export yield
DE19530865A1 (en)	1995-08-22	1997-02-27	Michael Dr Med Nauck	Active ingredient and agent for parenteral nutrition
JPH0995455A (en)	1995-09-29	1997-04-08	Sumitomo Pharmaceut Co Ltd	Renal function improving agent
US5766620A (en) *	1995-10-23	1998-06-16	Theratech, Inc.	Buccal delivery of glucagon-like insulinotropic peptides
US5849322A (en)	1995-10-23	1998-12-15	Theratech, Inc.	Compositions and methods for buccal delivery of pharmaceutical agents
US5702717A (en)	1995-10-25	1997-12-30	Macromed, Inc.	Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
WO1997016204A1 (en)	1995-11-02	1997-05-09	Schering Corporation	Continuous low-dose cytokine infusion therapy
US6048964A (en) *	1995-12-12	2000-04-11	Stryker Corporation	Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US6080409A (en)	1995-12-28	2000-06-27	Dendreon Corporation	Immunostimulatory method
GB9526733D0 (en)	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
US6087129A (en)	1996-01-19	2000-07-11	Betagene, Inc.	Recombinant expression of proteins from secretory cell lines
CA2246431A1 (en)	1996-01-19	1997-07-24	Board Of Regents, The University Of Texas System	Recombinant expression of proteins from secretory cell lines
US6110707A (en)	1996-01-19	2000-08-29	Board Of Regents, The University Of Texas System	Recombinant expression of proteins from secretory cell lines
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6150337A (en)	1996-01-23	2000-11-21	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
JP2978435B2 (en)	1996-01-24	1999-11-15	チッソ株式会社	Method for producing acryloxypropyl silane
US5616724A (en)	1996-02-21	1997-04-01	Cephalon, Inc.	Fused pyrrolo[2,3-c]carbazole-6-ones
US6045788A (en) *	1996-02-28	2000-04-04	Cornell Research Foundation, Inc.	Method of stimulation of immune response with low doses of IL-2
DE19639601A1 (en)	1996-02-28	1997-09-04	Bayer Ag	Parapox viruses that contain foreign DNA, their production and their use in vaccines
BR9707807A (en)	1996-03-01	1999-07-27	Novo Nordisk As	Use of a pharmaceutical composition pharmaceutical composition process of treating diseases or disorders associated with the regulation of impaired appetite and use of a peptide
US5912229A (en) *	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
JP3794748B2 (en) *	1996-03-04	2006-07-12	第一アスビオファーマ株式会社	Method for culturing microorganisms with methanol metabolism
WO1997033904A1 (en)	1996-03-12	1997-09-18	Human Genome Sciences, Inc.	Death domain containing receptors
KR100447374B1 (en)	1996-03-13	2004-11-03	델타 바이오테크놀로지 리미티드	How to control fermentation
AU5711196A (en)	1996-03-14	1997-10-01	Human Genome Sciences, Inc.	Apoptosis inducing molecule i
WO1997033998A1 (en)	1996-03-14	1997-09-18	The Immune Response Corporation	Targeted delivery of genes encoding interferon
WO1997034997A1 (en)	1996-03-21	1997-09-25	Human Genome Sciences, Inc.	Human endometrial specific steroid-binding factor i, ii and iii
KR20030096450A (en)	1996-03-22	2003-12-31	휴먼 게놈 사이언시즈, 인코포레이티드	Apoptosis inducing molecule ii
US6204022B1 (en) *	1996-04-12	2001-03-20	Pepgen Corporation And University Of Florida	Low-toxicity human interferon-alpha analogs
AU2667197A (en)	1996-04-16	1997-11-07	University Of Miami	Stabilized preparations of human troponins and modifications thereof, diagnostic assay methods and assay kits
EP0966971A1 (en) *	1996-04-23	1999-12-29	Chugai Seiyaku Kabushiki Kaisha	Cerebral stroke/cerebral edema preventive or remedy containing il-8 binding inhibitor as active ingredient
CA2255615C (en) *	1996-05-22	2006-08-29	Neuromedica, Inc.	Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
US5919815A (en)	1996-05-22	1999-07-06	Neuromedica, Inc.	Taxane compounds and compositions
US6300065B1 (en)	1996-05-31	2001-10-09	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
ATE277172T1 (en) *	1996-06-11	2004-10-15	Roche Diagnostics Gmbh	RECOMBINANT BLOOD CLOTTING PROTEASES
US6110891A (en)	1996-06-21	2000-08-29	Alizyme Therapeutics Ltd.	Lectin compositions and uses thereof
GB2318352A (en)	1996-06-25	1998-04-22	Dejan Markovic	Polypeptides mimicking the activity of human erythropoietin
GB9613858D0 (en)	1996-07-02	1996-09-04	Cortecs Ltd	Hydrophobic preparations
US5932547A (en)	1996-07-03	1999-08-03	Alza Corporation	Non-aqueous polar aprotic peptide formulations
US6110703A (en)	1996-07-05	2000-08-29	Novo Nordisk A/S	Method for the production of polypeptides
US6828426B1 (en)	1996-07-15	2004-12-07	Chugai Seiyaku Kabushiki Kaisha	VEGF-like factor
MY120425A (en)	1996-07-26	2005-10-31	Novartis Ag	Fusion polypeptides
WO1998005782A1 (en)	1996-08-02	1998-02-12	Zymogenetics, Inc.	Testis-specific insulin homolog polypeptides
US6190533B1 (en)	1996-08-15	2001-02-20	Exxon Chemical Patents Inc.	Integrated hydrotreating steam cracking process for the production of olefins
AU4055697A (en)	1996-08-16	1998-03-06	Schering Corporation	Mammalian cell surface antigens; related reagents
EP2025682A3 (en)	1996-08-16	2009-06-17	Human Genome Sciences, Inc.	Human endokine alpha
ES2251740T3 (en)	1996-08-23	2006-05-01	Ludwig Institute For Cancer Research	GROWTH FACTOR OF VASCULAR D RECOMBINANT ENDOTHELIAL CELLS (VEGF-D).
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6458924B2 (en)	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
US5922761A (en)	1996-09-06	1999-07-13	Medinox, Inc.	Methods for in vivo reduction of iron levels and compositions useful therefor
WO1998011136A1 (en)	1996-09-09	1998-03-19	Novo Nordisk A/S	A cDNA AND PEPTIDE WITH RELATION TO CANCER AND WEIGHT LOSS
US20020052309A1 (en)	1996-09-11	2002-05-02	Athanasius A. Anagnostou	Method of treating endothelial injury
WO1998012344A1 (en) *	1996-09-18	1998-03-26	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like genes
US6225290B1 (en)	1996-09-19	2001-05-01	The Regents Of The University Of California	Systemic gene therapy by intestinal cell transformation
US5994112A (en)	1996-10-09	1999-11-30	Incyte Pharmaceuticals, Inc.	Human protein tyrosine kinase
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
US5955508A (en) *	1996-10-15	1999-09-21	Loyola University Of Chicago	Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens
KR20060079258A (en)	1996-10-18	2006-07-05	제넨테크, 인크.	Anti-ER2 antibody
AU4988697A (en)	1996-10-24	1998-05-15	Vion Pharmaceuticals, Inc.	Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
CA2266439C (en)	1996-10-25	2009-06-16	Human Genome Sciences, Inc.	Neutrokine .alpha.
JPH10134761A (en)	1996-10-30	1998-05-22	Ebara Corp	Ion implantation apparatus and ion implantation method
US5908830A (en) *	1996-10-31	1999-06-01	Merck & Co., Inc.	Combination therapy for the treatment of diabetes and obesity
UA65549C2 (en)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
EP1306092A3 (en)	1996-11-05	2003-05-07	Eli Lilly & Company	Use of GLP-1 and analogs administered peripherally, in regulation of obesity
GB9623205D0 (en) *	1996-11-07	1997-01-08	Eurand Int	Novel pharmaceutical compositions
DE69737916T2 (en)	1996-11-12	2008-04-03	Novo Nordisk A/S	Use of GLP-1 peptides
DK1500329T3 (en)	1996-12-03	2012-07-09	Amgen Fremont Inc	Human antibodies that specifically bind TNF-alpha
US6130248A (en)	1996-12-30	2000-10-10	Bar-Ilan University	Tricarboxylic acid-containing oxyalkyl esters and uses thereof
US5833994A (en)	1997-01-08	1998-11-10	Paracelsian, Inc.	Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
ATE321855T1 (en)	1997-01-14	2006-04-15	Human Genome Sciences Inc	TUMOR NECROSIS FACTOR RECEPTOR 5
WO1998032867A1 (en)	1997-01-24	1998-07-30	Novo Nordisk A/S	Synthetic leader peptide sequences
EP1862548A1 (en)	1997-01-28	2007-12-05	Human Genome Sciences, Inc.	Death domain containing receptor 4 (DR4 : death receptor 4), member of the TNF-receptor superfamily and binding to trail (APO2-L)
ATE200030T1 (en)	1997-01-29	2001-04-15	Polymasc Pharmaceuticals Plc	PEGYLATION PROCEDURE
EP0981635A1 (en)	1997-02-13	2000-03-01	Applied Phytologics, Inc.	Production of mature proteins in plants
GB2324529A (en)	1997-02-21	1998-10-28	Merck & Co Inc	A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases
US7026447B2 (en)	1997-10-09	2006-04-11	Human Genome Sciences, Inc.	53 human secreted proteins
US5939455A (en)	1997-03-11	1999-08-17	Beacon Laboratories, Inc.	Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US6110955A (en)	1997-03-11	2000-08-29	Beacon Laboratories, Inc.	Metabolically stabilized oxyalkylene esters and uses thereof
US6124495A (en)	1997-03-11	2000-09-26	Beacon Laboratories, Inc.	Unsaturated oxyalkylene esters and uses thereof
US6030961A (en) *	1997-03-11	2000-02-29	Bar-Ilan Research & Development Co., Ltd.	Oxyalkylene phosphate compounds and uses thereof
US6110970A (en)	1997-03-11	2000-08-29	Beacon Laboratories, Inc.	Nitrogen-containing oxyalkylene esters and uses thereof
US5846774A (en)	1997-03-21	1998-12-08	Bionebraska, Inc.	Chlorella virus promoters
US5981488A (en)	1997-03-31	1999-11-09	Eli Lillly And Company	Glucagon-like peptide-1 analogs
DK0970126T3 (en)	1997-04-14	2001-08-13	Micromet Ag	Hitherto unknown method for the preparation of anti-human antigen receptors and uses thereof
MY118835A (en)	1997-04-18	2005-01-31	Ipsen Pharma Biotech	Sustained release compositions and the process for their preparation
US6140368A (en)	1997-05-05	2000-10-31	The Regents Of The University Of California	Naphthols useful in antiviral methods
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
US6214580B1 (en)	1997-05-30	2001-04-10	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor tr10
US6071743A (en)	1997-06-02	2000-06-06	Subsidiary No. 3, Inc.	Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
EP0988371A4 (en)	1997-06-11	2002-11-04	Human Genome Sciences Inc	Human tumor necrosis factor receptor tr9
GB9713412D0 (en)	1997-06-26	1997-08-27	Delta Biotechnology Ltd	Improved protein expression strains
US5858719A (en)	1997-07-17	1999-01-12	Incyte Pharmaceuticals, Inc.	Polynucleotides encoding human ATP binding-cassette transport protein and methods of use
DE69726571T2 (en)	1997-09-01	2004-11-04	Aventis Pharma Deutschland Gmbh	Recombinant human erythropoietin with an advantageous glycosylation pattern
HUP9701554D0 (en)	1997-09-18	1997-11-28	Human Oltoanyagtermeloe Gyogys	Pharmaceutical composition containing plazma proteins
US6172046B1 (en) *	1997-09-21	2001-01-09	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
EP1317929A3 (en)	1997-09-21	2003-07-02	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis c infection
US6472373B1 (en)	1997-09-21	2002-10-29	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
CA2304808C (en)	1997-09-23	2011-03-22	Michael Tschope	Liquid interferon-.beta. formulations
US6201072B1 (en) *	1997-10-03	2001-03-13	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en)	1998-10-01	2000-09-12	Macromed, Inc.	Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6004573A (en)	1997-10-03	1999-12-21	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
JP2001519179A (en) *	1997-10-09	2001-10-23	ヒューマンジノームサイエンシーズ，インコーポレイテッド	53 human secreted proteins
MXPA00004256A (en)	1997-11-03	2005-07-01	Human Genome Sciences Inc	Vegi, an inhibitor of angiogenesis and tumor growth.
ES2523599T3 (en)	1997-12-03	2014-11-27	Roche Diagnostics Gmbh	Erythropoietin of great specific activity
JP2001525371A (en)	1997-12-05	2001-12-11	イーライ・リリー・アンド・カンパニー	GLP-1 preparation
DE69824039T2 (en)	1997-12-08	2005-08-18	Lexigen Pharmaceuticals Corp., Lexington	HETERODIMARY FUSION PROTEINS FOR THE USE OF TARGETED IMMUNOTHERAPY AND GENERAL IMMUNE REGION
ES2216335T3 (en) *	1997-12-08	2004-10-16	Bristol-Myers Squibb Company	NEW METFORMIN SALTS AND PROCEDURE.
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
KR100253916B1 (en)	1997-12-29	2000-05-01	김충환	Method for preparing human insulin precursor
US5951996A (en)	1998-02-04	1999-09-14	Czeizler Zaharia; Veronica L.	Treatment of chronic diffuse GI bleeding with erythropoietin
US6221378B1 (en) *	1998-02-10	2001-04-24	Generex Pharmaceuticals Incorporated	Mixed micellar delivery system and method of preparation
US6017545A (en) *	1998-02-10	2000-01-25	Modi; Pankaj	Mixed micellar delivery system and method of preparation
DE69936446T2 (en)	1998-02-13	2008-03-06	Amylin Pharmaceuticals, Inc., San Diego	INOTROPIC AND DIETIC EFFECTS OF EXENDIN AND GLP-1
AU2610699A (en)	1998-02-27	1999-09-15	Novo Nordisk A/S	Derivatives of glp-1 analogs
EP1061947B1 (en)	1998-03-13	2004-06-16	Novo Nordisk A/S	Stabilized aqueous glucagon solutions comprising detergents
WO1999047161A1 (en)	1998-03-19	1999-09-23	Bionebraska, Inc.	Human appetite control by glucagon-like peptide receptor binding compounds
DE19813802A1 (en)	1998-03-27	1999-11-11	Retro Tech Gmbh	Anti-viral effects of propolis through inhibition of viral nucleic acid polymerases
GB9806631D0 (en)	1998-03-28	1998-05-27	Safeglass Europ Limited	Safetyglass
WO1999053064A2 (en)	1998-04-13	1999-10-21	Modex Therapeutiques, S.A.	Methods of delivering glp-1
CA2270320A1 (en)	1998-04-28	1999-10-28	Patricia Lee Brubaker	Novel microsphere composition
US6251868B1 (en)	1998-04-30	2001-06-26	Teijin Limited	Method for treating a human immunodeficiency virus infection
ATE216591T1 (en) *	1998-05-15	2002-05-15	Schering Corp	COMBINATION THERAPY CONTAINING RIBAVIRIN AND INTERFERON ALPHA IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION WHO ARE NOT PREVIOUSLY TREATED WITH ANTIVIRALS
CN1119352C (en)	1998-05-15	2003-08-27	中国科学院上海生物化学研究所	Express and purification of human serum albumin in pichia
US5970300A (en) *	1998-06-01	1999-10-19	Xerox Corporation	Apparatus for applying scents to paper in a printer/copier
SE9802080D0 (en)	1998-06-11	1998-06-11	Hellstroem	Pharmaceutical composition for the treatment of functional dyspepsia and / or irritable bowel syndrome and new use of substances therein
ES2224659T3 (en)	1998-06-12	2005-03-01	Amylin Pharmaceuticals, Inc.	GLUCAGON TYPE I PEPTIDE (GLP-1) IMPROVES THE RESPONSE OF BETA GLUCOSE CELLS IN SUBJECTS WITH TOLERANCE DETERIORATED TO GLUCOSE.
ATE339507T1 (en)	1998-06-15	2006-10-15	Gtc Biotherapeutics Inc	ERYTHROPOIETIN ANALOG HUMAN SERUM-ALBUMIN FUSION PROTEIN
CN1105727C (en)	1998-06-17	2003-04-16	上海海济医药生物工程有限公司	Production method of recombinant human serum albumin
WO1999066936A1 (en)	1998-06-24	1999-12-29	Emory University	Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
AU758496B2 (en)	1998-06-30	2003-03-20	Novo Nordisk A/S	Seeding crystals for the preparation of peptides or proteins
WO2000004171A1 (en)	1998-07-15	2000-01-27	Wisconsin Alumni Research Foundation	Treatment of diabetes with synthetic beta cells
EP1306091A3 (en)	1998-07-31	2003-05-21	Novo Nordisk A/S	Stimulation of beta cell proliferation
GB9817084D0 (en)	1998-08-06	1998-10-07	Wood Christopher B	A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders
EP1105460B1 (en)	1998-08-10	2009-10-07	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
US6346543B1 (en) *	1998-08-17	2002-02-12	Aventis Pharma S.A.	Use of a taxoid to treat abnormal cell proliferation in the brain
HRP20010141A2 (en)	1998-08-28	2002-02-28	Lilly Co Eli	Method for administering insulinotropic peptides
MY155270A (en)	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
US6193997B1 (en) *	1998-09-27	2001-02-27	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using membrane mimetics
US6290987B1 (en)	1998-09-27	2001-09-18	Generex Pharmaceuticals, Inc.	Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6429197B1 (en)	1998-10-08	2002-08-06	Bionebraska, Inc.	Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
AU772460B2 (en)	1998-10-16	2004-04-29	Immunex Corporation	Inhibitors of platelet activation and recruitment
ATE355303T1 (en)	1998-10-23	2006-03-15	Amgen Inc	METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF ANEMIA
AU774156B2 (en)	1998-10-30	2004-06-17	Novozymes A/S	Glycosylated proteins having reduced allergenicity
JP2002531089A (en)	1998-11-30	2002-09-24	イーライ・リリー・アンド・カンパニー	Erythropoietic compounds
US6048891A (en) *	1998-12-17	2000-04-11	Loma Linda University Medical Center	Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6312665B1 (en)	1998-12-21	2001-11-06	Generex Pharmaceuticals Incorporated	Aerosol formulations for buccal and pulmonary application
US6271200B1 (en)	1998-12-21	2001-08-07	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
US6294153B1 (en)	1998-12-21	2001-09-25	Generex Pharmaceuticals, Inc.	Aerosol pharmaceutical formulation for pulmonary and nasal delivery
ATE307603T1 (en)	1998-12-22	2005-11-15	Lilly Co Eli	STORAGE STABLE LIQUID COMPOSITIONS OF GLUCAGON-LIKE PEPTIDE-1
GB9902000D0 (en)	1999-01-30	1999-03-17	Delta Biotechnology Ltd	Process
US7109292B2 (en) *	1999-03-08	2006-09-19	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003500018A (en)	1999-04-09	2003-01-07	ヒューマンジノームサイエンシーズ，インコーポレイテッド	48 human secreted proteins
JP2002542183A (en)	1999-04-16	2002-12-10	ノボノルディスクアクティーゼルスカブ	Moldable dry pharmaceutical formulation
US6287588B1 (en)	1999-04-29	2001-09-11	Macromed, Inc.	Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6348192B1 (en) *	1999-05-11	2002-02-19	Bayer Corporation	Interleukin-2 mutein expressed from mammalian cells
DE19921537A1 (en)	1999-05-11	2000-11-23	Dieter Hoersch	Treating carbohydrate metabolism disorders, especially diabetes, comprises activating insulin-secreting b-cells using glucagon-related peptide, glucose-dependent insulinotropic polypeptide, exendin-4 or related drugs
DK1180121T3 (en)	1999-05-17	2004-03-01	Conjuchem Inc	Long-acting insulinotropic peptides
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
DK1187852T3 (en)	1999-05-19	2007-11-26	Merck Patent Gmbh	Expression and export of interferon alpha proteins as Fc fusion proteins
US6344180B1 (en)	1999-06-15	2002-02-05	Bionebraska, Inc.	GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
SI1133312T1 (en)	1999-06-21	2008-02-29	Lilly Co Eli	Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes
PE20010288A1 (en)	1999-07-02	2001-03-07	Hoffmann La Roche	ERYTHROPOYETIN DERIVATIVES
US20020048571A1 (en) *	1999-07-19	2002-04-25	Jeno Gyuris	Chimeric polypeptides of serum albumin and uses related thereto
EP1200608A2 (en)	1999-07-19	2002-05-02	GPC Biotech Inc.	Chimeric polypeptides of serum albumin and uses related thereto
CA2382148A1 (en)	1999-08-17	2001-02-22	Human Genome Sciences, Inc.	25 human secreted proteins
US7144574B2 (en) *	1999-08-27	2006-12-05	Maxygen Aps	Interferon β variants and conjugates
TW200514783A (en)	1999-09-22	2005-05-01	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
CA2388432A1 (en)	1999-10-21	2001-04-26	Monsanto Company	Post-translational modification of recombinant proteins produced in plants
AU1226901A (en)	1999-10-22	2001-05-08	Amgen, Inc.	Biodegradable microparticles with novel erythropoietin stimulating protein
JP2003534237A (en)	1999-11-03	2003-11-18	ノボノルディスクアクティーゼルスカブ	Use of growth hormone or growth hormone secretagogue for suppressing appetite or inducing satiety
CA2324801A1 (en)	1999-11-10	2001-05-10	Andrew Gordon Swick	Use of apo b secretion/mtp inhibitors and anti-obesity agents
US6569832B1 (en) *	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
AU2154401A (en)	1999-11-12	2001-05-30	Merck Patent Gmbh	Erythropoietin forms with improved properties
AU778929B2 (en)	1999-12-06	2004-12-23	General Hospital Corporation, The	Pancreatic stem cells and their use in transplantation
US20020025306A1 (en)	2000-01-07	2002-02-28	Baetge Edward E.	Methods of increasing the glucose responsiveness of pancreatic ss-cells
EP1125579A3 (en)	2000-01-18	2003-01-02	Pfizer Products Inc.	Uses of agrp-melanocortin receptor binding modulating compounds
AU2001232735A1 (en)	2000-01-27	2001-08-07	Eli Lilly And Company	Process for solubilizing glucagon-like peptide 1 compounds
WO2001057084A1 (en)	2000-01-31	2001-08-09	Novo Nordisk A/S	Crystallisation of a glp-1 analogue
KR20030009389A (en)	2000-03-14	2003-01-29	브루카드 괴케	Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
US20050100991A1 (en)	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
ES2484966T3 (en)	2000-04-12	2014-08-12	Novozymes Biopharma Dk A/S	Albumin fusion proteins
DE60134003D1 (en)	2000-04-21	2008-06-26	Amgen Inc	METHOD AND COMPOSITIONS FOR AVOIDING AND TREATING ANEMIA
IL142707A0 (en)	2000-04-27	2002-03-10	Pfizer Prod Inc	Methods of treating obesity using a neurotensin receptor ligand
PT1311285E (en) *	2000-05-15	2005-06-30	Hoffmann La Roche	Liquid pharmaceutical composition containing a derivative of erythropoietin
CA2380423A1 (en)	2000-05-17	2001-11-22	Bionebraska, Inc.	Peptide pharmaceutical formulations
ATE346093T1 (en)	2000-06-16	2006-12-15	Lilly Co Eli	ANALOGUE OF GLUCAGON-LIKE PEPTIDE-1
PT1326630E (en)	2000-09-18	2008-09-02	Sanos Bioscience As	Use of glp-2 peptides
US7101561B2 (en) *	2000-12-01	2006-09-05	Innogenetics N.V.	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AU2002221222A1 (en)	2000-12-04	2002-06-18	Biovitrum Ab	Novel method and use
JP2004528014A (en)	2000-12-07	2004-09-16	イーライ・リリー・アンド・カンパニー	GLP-1 fusion protein
EP1351984A2 (en)	2000-12-13	2003-10-15	Eli Lilly And Company	Amidated glucagon-like peptide-1
AU2002239384B2 (en)	2000-12-13	2007-01-11	Eli Lilly And Company	Chronic treatment regimen using glucagon-like insulinotropic peptides
US7070973B2 (en)	2000-12-26	2006-07-04	Board Of Regents Of The University Of Nebraska	Butyrylcholinesterase variants and methods of use
WO2002066062A2 (en)	2001-02-01	2002-08-29	Drucker Daniel J	Enhancement of glp-2 activity
KR100399337B1 (en)	2001-02-07	2003-09-26	드림바이오젠 주식회사	Method for Cell-free Protein Post-translational Modification
AU2002235731A1 (en)	2001-03-07	2002-09-19	Novo Nordisk A/S	Combined use of derivatives of glp-1 analogs and ppar ligands
US20020169128A1 (en)	2001-04-09	2002-11-14	Geroge Sigounas	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US20050054051A1 (en)	2001-04-12	2005-03-10	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060084794A1 (en) *	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050244931A1 (en)	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2002085406A1 (en)	2001-04-24	2002-10-31	Restoragen, Inc.	Methods and compositions for treating conditions associated with insulin resistance
EP1401477A4 (en)	2001-05-25	2005-02-02	Human Genome Sciences	Chemokine beta-1 fusion proteins
US7144863B2 (en)	2001-06-01	2006-12-05	Eli Lilly And Company	GLP-1 formulations with protracted time action
EP1397124B1 (en)	2001-06-20	2006-11-29	Merck Sante	Use of antidiabetics for making a medicine with cicatrizing effect
WO2003002136A2 (en)	2001-06-28	2003-01-09	Novo Nordisk A/S	Stable formulation of modified glp-1
EP1411968B1 (en)	2001-07-31	2008-09-17	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Glp-1 exendin-4 peptide analogs and uses thereof
AU2002327430A1 (en)	2001-08-08	2003-02-24	Genzyme Corporation	Methods for treating diabetes and other blood sugar disorders
US7186797B2 (en)	2001-08-10	2007-03-06	Epix Pharmaceuticals, Inc.	Polypeptide conjugates with extended circulating half-lives
BR0212080A (en)	2001-08-23	2006-04-04	Lilly Co Eli	glp-1 compound, method of glp-1 receptor stimulation in an individual in need of such stimulation, and use of a glp-1 compound
WO2003030821A2 (en)	2001-10-05	2003-04-17	Human Genome Sciences, Inc.	Albumin fusion proteins
IL161251A0 (en) *	2001-10-10	2004-09-27	Neose Technologies Inc	Remodeling and glycoconjugation of peptides
EP2277888A3 (en) *	2001-12-21	2011-04-27	Human Genome Sciences, Inc.	Fusion proteins of albumin and erythropoietin
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
US20080194481A1 (en)	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
AU2002364587A1 (en)	2001-12-21	2003-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2003054182A2 (en)	2001-12-21	2003-07-03	Nexia Biotechnologies, Inc.	Production of butyrylcholinesterases in transgenic mammals
KR101271635B1 (en) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	Albumin fusion proteins
US20080167238A1 (en)	2001-12-21	2008-07-10	Human Genome Sciences, Inc.	Albumin Fusion Proteins
EP1572936A2 (en)	2002-03-05	2005-09-14	Eli Lilly And Company	Heterologous g-csf fusion proteins
MXPA04012496A (en) *	2002-06-21	2005-09-12	Novo Nordisk Healthcare Ag	Pegylated factor vii glycoforms.
CN1241946C (en) *	2002-07-01	2006-02-15	美国福源集团	Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells
US6913890B2 (en) *	2002-12-18	2005-07-05	Palo Alto Research Center Incorporated	Process for preparing albumin protein conjugated oligonucleotide probes
EP1596888B1 (en) *	2003-02-27	2012-01-11	Baxter International Inc.	Method for the validatable inactivation of pathogens in a biological fluid by irradiation
US7452966B2 (en)	2003-06-12	2008-11-18	Eli Lilly And Company	GLP-1 analog fusion proteins
JP5010923B2 (en)	2004-02-09	2012-08-29	ヒューマンジノームサイエンシーズ，インコーポレイテッド	Albumin fusion protein
US20060051859A1 (en) *	2004-09-09	2006-03-09	Yan Fu	Long acting human interferon analogs
US7436410B2 (en) *	2005-04-01	2008-10-14	Seiko Epson Corporation	System and method for programming a controller
MX2008001865A (en)	2005-08-12	2008-04-15	Human Genome Sciences Inc	Albumin fusion proteins.
US7438904B1 (en)	2005-10-04	2008-10-21	University Of Kentucky Research Foundation	High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same
US8008257B2 (en)	2005-10-20	2011-08-30	University Of Ottawa Heart Institute	ANF fusion proteins
EP1816201A1 (en) *	2006-02-06	2007-08-08	CSL Behring GmbH	Modified coagulation factor VIIa with extended half-life
US8334365B2 (en)	2006-06-07	2012-12-18	Human Genome Sciences, Inc.	Albumin fusion proteins
PL2717898T3 (en) *	2011-06-10	2019-06-28	Bioverativ Therapeutics Inc.	Pro-coagulant compounds and methods of use thereof

2001
- 2001-04-12 ES ES10075010.8T patent/ES2484966T3/en not_active Expired - Lifetime
- 2001-04-12 WO PCT/US2001/012009 patent/WO2001079271A1/en not_active Ceased
- 2001-04-12 AU AU2001262942A patent/AU2001262942A1/en not_active Abandoned
- 2001-04-12 CA CA002405709A patent/CA2405709A1/en not_active Abandoned
- 2001-04-12 AU AU2001259063A patent/AU2001259063A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011850 patent/WO2001079442A2/en not_active Ceased
- 2001-04-12 WO PCT/US2001/012013 patent/WO2001079444A2/en not_active Ceased
- 2001-04-12 AU AU2001274809A patent/AU2001274809A1/en not_active Abandoned
- 2001-04-12 AU AU2001261024A patent/AU2001261024A1/en not_active Abandoned
- 2001-04-12 CA CA002405912A patent/CA2405912A1/en not_active Abandoned
- 2001-04-12 EP EP10075499A patent/EP2357008A1/en not_active Withdrawn
- 2001-04-12 AU AU2001264563A patent/AU2001264563A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011988 patent/WO2001077137A1/en not_active Ceased
- 2001-04-12 JP JP2001576866A patent/JP2003530839A/en active Pending
- 2001-04-12 EP EP08075327A patent/EP1983055A1/en not_active Withdrawn
- 2001-04-12 JP JP2001577427A patent/JP2003530846A/en active Pending
- 2001-04-12 JP JP2001576855A patent/JP2003530838A/en active Pending
- 2001-04-12 EP EP06076852A patent/EP1832599A3/en not_active Ceased
- 2001-04-12 CA CA2747325A patent/CA2747325A1/en not_active Abandoned
- 2001-04-12 CA CA002405701A patent/CA2405701A1/en not_active Withdrawn
- 2001-04-12 US US09/832,929 patent/US6926898B2/en not_active Expired - Lifetime
- 2001-04-12 EP EP01937179A patent/EP1276856A4/en not_active Withdrawn
- 2001-04-12 ES ES10075011.6T patent/ES2529300T3/en not_active Expired - Lifetime
- 2001-04-12 CA CA2405557A patent/CA2405557C/en not_active Expired - Lifetime
- 2001-04-12 EP EP08075909A patent/EP2067488A1/en not_active Withdrawn
- 2001-04-12 CA CA002405550A patent/CA2405550A1/en not_active Abandoned
- 2001-04-12 EP EP01932549A patent/EP1274720A4/en not_active Ceased
- 2001-04-12 EP EP10075010.8A patent/EP2236152B1/en not_active Expired - Lifetime
- 2001-04-12 EP EP01932546A patent/EP1274719A4/en not_active Ceased
- 2001-04-12 AU AU2001266557A patent/AU2001266557A1/en not_active Abandoned
- 2001-04-12 EP EP10075164A patent/EP2213743A1/en not_active Withdrawn
- 2001-04-12 EP EP01944114A patent/EP1276756A4/en not_active Withdrawn
- 2001-04-12 JP JP2001575607A patent/JP2004506407A/en active Pending
- 2001-04-12 JP JP2001577463A patent/JP2003530852A/en active Pending
- 2001-04-12 EP EP10075388A patent/EP2311872A1/en not_active Withdrawn
- 2001-04-12 JP JP2001577426A patent/JP2003531590A/en active Pending
- 2001-04-12 EP EP10075011.6A patent/EP2216409B1/en not_active Expired - Lifetime
- 2001-04-12 WO PCT/US2001/012008 patent/WO2001079258A1/en not_active Ceased
- 2001-04-12 EP EP06015131A patent/EP1803730A1/en not_active Withdrawn
- 2001-04-12 CA CA002405525A patent/CA2405525A1/en not_active Abandoned
- 2001-04-12 US US09/833,245 patent/US20040010134A1/en not_active Abandoned
- 2001-04-12 US US09/833,117 patent/US20030171267A1/en not_active Abandoned
- 2001-04-12 DK DK10075011.6T patent/DK2216409T3/en active
- 2001-04-12 EP EP01934875A patent/EP1278767A4/en not_active Withdrawn
- 2001-04-12 EP EP10075316A patent/EP2275557A1/en not_active Withdrawn
- 2001-04-12 US US09/833,118 patent/US6905688B2/en not_active Expired - Lifetime
- 2001-04-12 DK DK10075010.8T patent/DK2236152T3/en active
- 2001-04-12 US US09/832,501 patent/US20030199043A1/en not_active Abandoned
- 2001-04-12 EP EP10075391A patent/EP2295456A1/en not_active Ceased
- 2001-04-12 JP JP2001577428A patent/JP2003530847A/en active Pending
- 2001-04-12 EP EP10075387A patent/EP2267026A1/en not_active Withdrawn
- 2001-04-12 US US09/833,041 patent/US6994857B2/en not_active Expired - Lifetime
- 2001-04-12 EP EP10075064A patent/EP2206720A1/en not_active Withdrawn
- 2001-04-12 CA CA002405563A patent/CA2405563A1/en not_active Abandoned
- 2001-04-12 EP EP01941457A patent/EP1278544A4/en not_active Ceased
- 2001-04-12 EP EP01938994A patent/EP1276849A4/en not_active Withdrawn
- 2001-04-12 EP EP10075375A patent/EP2298355A3/en not_active Withdrawn
- 2001-04-12 AU AU2001259066A patent/AU2001259066A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011924 patent/WO2001079443A2/en not_active Ceased
- 2001-04-12 WO PCT/US2001/011991 patent/WO2001079480A1/en not_active Ceased
2005
- 2005-03-14 US US11/078,663 patent/US7507414B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/078,914 patent/US7482013B2/en not_active Expired - Lifetime
2007
- 2007-10-29 US US11/927,617 patent/US20080269128A1/en not_active Abandoned
- 2007-10-29 US US11/927,583 patent/US20120141415A1/en not_active Abandoned
- 2007-10-29 US US11/927,602 patent/US10080785B2/en not_active Expired - Lifetime
- 2007-10-29 US US11/927,607 patent/US20080269126A1/en not_active Abandoned
- 2007-10-29 US US11/927,600 patent/US9821039B2/en not_active Expired - Fee Related
- 2007-10-29 US US11/927,555 patent/US20090285816A9/en not_active Abandoned
- 2007-10-29 US US11/927,593 patent/US20080261877A1/en not_active Abandoned
- 2007-10-29 US US11/927,610 patent/US20080269127A1/en not_active Abandoned
- 2007-10-30 US US11/929,677 patent/US7785599B2/en not_active Expired - Fee Related
2009
- 2009-02-04 US US12/365,878 patent/US20110280830A9/en not_active Abandoned
2011
- 2011-05-16 JP JP2011109620A patent/JP2011217750A/en active Pending
- 2011-08-18 US US13/212,879 patent/US20120252732A1/en not_active Abandoned
2012
- 2012-05-04 US US13/464,248 patent/US8946156B2/en not_active Expired - Fee Related
2013
- 2013-04-02 US US13/855,454 patent/US9849162B2/en not_active Expired - Fee Related
- 2013-04-02 US US13/855,434 patent/US9775888B2/en not_active Expired - Fee Related
- 2013-10-17 JP JP2013216509A patent/JP2014057589A/en active Pending
2016
- 2016-11-04 FR FR16C0043C patent/FR16C0043I2/en active Active
- 2016-11-04 BE BE2016C059C patent/BE2016C059I2/nl unknown
2017
- 2017-12-21 US US15/850,371 patent/US20180200346A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2206720A1 (en)	2010-07-14
CA2747325A1 (en)	2001-10-25
WO2001079442A3 (en)	2002-06-06
EP2216409A1 (en)	2010-08-11
US20030199043A1 (en)	2003-10-23
WO2001079444A2 (en)	2001-10-25
FR16C0043I2 (en)	2020-04-10
ES2529300T3 (en)	2015-02-18
EP1274720A1 (en)	2003-01-15
EP1274719A4 (en)	2004-05-19
US20040171123A1 (en)	2004-09-02
BE2016C059I2 (en)	2020-08-20
US20090285816A9 (en)	2009-11-19
EP1276849A4 (en)	2004-06-09
US20080269126A1 (en)	2008-10-30
WO2001079442A2 (en)	2001-10-25
US20080261877A1 (en)	2008-10-23
WO2001079480A9 (en)	2003-09-18
US20140010798A1 (en)	2014-01-09
US20050266532A1 (en)	2005-12-01
US20030125247A1 (en)	2003-07-03
EP1278767A1 (en)	2003-01-29
EP2298355A3 (en)	2011-06-29
EP2067488A1 (en)	2009-06-10
FR16C0043I1 (en)	2016-12-09
JP2003530847A (en)	2003-10-21
WO2001079258A9 (en)	2002-02-28
US9821039B2 (en)	2017-11-21
ES2484966T3 (en)	2014-08-12
US9775888B2 (en)	2017-10-03
US20080267962A1 (en)	2008-10-30
US20110280830A9 (en)	2011-11-17
US20130266553A1 (en)	2013-10-10
EP2267026A1 (en)	2010-12-29
EP2216409B1 (en)	2014-12-03
US20120141415A1 (en)	2012-06-07
EP1983055A1 (en)	2008-10-22
US20100189686A1 (en)	2010-07-29
US10080785B2 (en)	2018-09-25
AU2001274809A1 (en)	2001-10-30
US20140004095A1 (en)	2014-01-02
JP2003531590A (en)	2003-10-28
EP1278767A4 (en)	2003-11-12
EP1274719A2 (en)	2003-01-15
EP1278544A4 (en)	2004-08-18
EP1832599A2 (en)	2007-09-12
US7507414B2 (en)	2009-03-24
JP2003530838A (en)	2003-10-21
US6926898B2 (en)	2005-08-09
US20080269125A1 (en)	2008-10-30
DK2216409T3 (en)	2015-01-05
US8946156B2 (en)	2015-02-03
WO2001079258A1 (en)	2001-10-25
US20120141449A1 (en)	2012-06-07
AU2001261024A1 (en)	2001-10-30
AU2001259063A1 (en)	2001-10-30
US9849162B2 (en)	2017-12-26
WO2001079271A9 (en)	2002-02-28
EP1274720A4 (en)	2004-08-18
EP2275557A1 (en)	2011-01-19
EP2357008A1 (en)	2011-08-17
EP1276856A4 (en)	2004-06-09
EP1276856A1 (en)	2003-01-22
US20030219875A1 (en)	2003-11-27
JP2003530846A (en)	2003-10-21
US20070287173A9 (en)	2007-12-13
EP1832599A3 (en)	2007-11-21
US7482013B2 (en)	2009-01-27
CA2405525A1 (en)	2001-10-25
WO2001079443A2 (en)	2001-10-25
JP2011217750A (en)	2011-11-04
JP2004506407A (en)	2004-03-04
WO2001077137A1 (en)	2001-10-18
WO2001079443A3 (en)	2002-02-21
AU2001266557A1 (en)	2001-10-23
CA2405563A1 (en)	2001-10-25
AU2001262942A1 (en)	2001-10-30
JP2014057589A (en)	2014-04-03
EP2311872A1 (en)	2011-04-20
EP1276849A2 (en)	2003-01-22
EP1278544A2 (en)	2003-01-29
US20080269127A1 (en)	2008-10-30
CA2405557C (en)	2013-09-24
CA2405912A1 (en)	2001-10-18
US20080131399A1 (en)	2008-06-05
US20030171267A1 (en)	2003-09-11
EP1803730A1 (en)	2007-07-04
DK2236152T3 (en)	2014-07-07
JP2003530852A (en)	2003-10-21
EP2213743A1 (en)	2010-08-04
EP1276756A4 (en)	2004-06-09
EP1276756A1 (en)	2003-01-22
US6905688B2 (en)	2005-06-14
EP2298355A2 (en)	2011-03-23
CA2405557A1 (en)	2001-10-25
JP2003530839A (en)	2003-10-21
US7785599B2 (en)	2010-08-31
CA2405550A1 (en)	2001-10-25
US6994857B2 (en)	2006-02-07
CA2405709A1 (en)	2001-10-25
US20050266533A1 (en)	2005-12-01
EP2236152A1 (en)	2010-10-06
US20080269128A1 (en)	2008-10-30
US20120252732A1 (en)	2012-10-04
AU2001259066A1 (en)	2001-10-30
US20040010134A1 (en)	2004-01-15
WO2001077137A9 (en)	2002-05-02
WO2001079444A3 (en)	2002-05-23
CA2405701A1 (en)	2001-10-25
US20180200346A1 (en)	2018-07-19
EP2295456A1 (en)	2011-03-16
WO2001079271A1 (en)	2001-10-25
WO2001079480A1 (en)	2001-10-25
EP2236152B1 (en)	2014-06-04

Publication	Publication Date	Title
AU2001259066A1 (en)	2001-10-30	Albumin fusion proteins
AU2002364586A1 (en)	2003-07-30	Albumin fusion proteins
AU2002364587A1 (en)	2003-07-30	Albumin fusion proteins
AU2002332041A1 (en)	2003-04-22	Albumin fusion proteins
AU2001291049A1 (en)	2002-03-26	Defensin-antigen fusion proteins
AU2002307255A1 (en)	2002-10-28	Vegf fusion proteins
HUP1300326A2 (en)	2003-10-28	Glp-1 fusion proteins
AU6058500A (en)	2001-01-31	Fusion protein and uses thereof
AU3562299A (en)	1999-11-23	Inhibin-hbc fusion protein
AU5553600A (en)	2001-01-31	Fusion proteins incorporating lysozyme
GB9913437D0 (en)	1999-08-11	Fusion proteins
AU9798398A (en)	1999-05-03	Gfp-annexin fusion proteins
IL148550A0 (en)	2002-09-12	Transgenically produced fusion proteins
AU2001291050A1 (en)	2002-03-26	Viral chemokine-tumur antigen fusion proteins
AU2002232707A1 (en)	2002-05-06	Transmembrane proteins
AU2002229675A1 (en)	2002-07-08	Selective cytotoxic fusion proteins
AU2002239747A1 (en)	2002-06-03	Cystoskeleton-associated proteins
AU2002224379A1 (en)	2002-04-22	Clasp-2 transmembrane proteins
AU2001261423A1 (en)	2001-11-20	Vasodilator-thrombolytic fusion proteins and conjugates
AU2001231918A1 (en)	2001-08-07	Scscntfr/nnt-1 fusion protein
AU2001241044A1 (en)	2001-09-17	Mitf-associated proteins
SI1463751T1 (en)	2013-11-29	Albumin fusion proteins
AU2755801A (en)	2001-07-16	Pp14 fusion proteins and methods for making and using the same
AU2001294911A1 (en)	2002-04-15	Carbohydrate-associated proteins
HK1080760A (en)	2006-05-04	Albumin fusion proteins